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 Abstract 
 
Nicotinic acetylcholine receptor (nAChR) activation in the spinal cord (SC) may cause 
hyperalgesia as well as analgesia, possibly depending on the concentration of nicotinic 
agonist being used. RT-PCR experiments have already suggested the expression of a fairly 
great number of subunits and hence of types of receptors in the rat spinal cord. We confirm 
that mRNA coding for the subunits α2, α3, α4, α5, α6, β2 and β4 is present in the mouse SC. 
This multiplicity allows, in principle, a great number of different nAChRs. The localization of 
these receptors, determined by immunohistochemical staining and autoradiography of SC 
kryosections, showed high densities in dorsal regions of the grey matter, where pain-
mediated pathways access the grey matter. In an attempt to assign the analgesic and 
hyperalgesic properties of nicotinic ligands to a particular type of receptor we have, in a first 
step, determined the subunit composition of nAChRs by [3H]-epibatidine binding, combined 
with single and/or sequential immunoprecipitation (IP). We used self-generated (rabbit) 
antibodies directed against the cytoplasmic loop. Our affinity-purified antibodies are 
extensively tested with recombinant receptors expressed in HEK293 cells, with materials 
taken from wild type (WT) mice, and - as a negative control - with materials from knock-out 
(KO) mice with deletions of distinct nAChR subunit genes. 
IP with the combined use of anti-β2 plus anti-β4 antibodies revealed a relatively low 
total number of 43.7 ± 1.16 fmol/mg protein binding sites in the spinal cord of WT C57Bl/6J 
mice. About 85 % of these receptors contain the subunits α4 and β2, whereas α3 co-
assembled with β4 to make up for about 10% of the receptors. Nonetheless, our data 
indicate that α3 also co-assembles into receptors that contain β2 (but not β4). The subunits 
α2 and α5 were measurable but occurred at low numbers only (2.5% and 2%, respectively), 
whereas α6-containing receptors could not be detected.     
These observations were confirmed by using mice with targeted deletions of the β2 
or the β4 subunit. In the β2 KO, overall receptor levels dropped to 10%, matching the 
amount of β4 – containing receptors in the wild-type. We did not detect any compensation 
for the dramatic loss of β2-containing receptors by any other subunit. Conversely, receptor 
frequency in β4 KO animals was similar to the wild-type.  
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The use of mouse KO models also permits an assessment of the kinetics of [3H]-epibatidine 
binding to defined (yet not recombinant) receptors in a membrane preparation.  
Hence, the Kd of α3β4* receptors analyzed in the SC of animals lacking β2 (160 ± 24 
pmol) was three times higher than in WT animals (53.7 ± 6 pmol), where most of the 
receptors are composed of α4 and β2. 
Overall, our observations show a fairly heterogeneous entity of nAChRs in the SC for 
which to find ligands that specifically mediate anti-nociception will be a demanding task.   
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Zusammenfassung 
 
Aktivierung des nikotinischen Azetylcholinrezeptors (nAChR) im Rückenmark (RM) 
kann, möglicherweise abhängig von der Konzentration des nikotinischen Agonisten, sowohl 
Analgesie als auch Hyperalgesie auslösen. RT-PCR Experimente haben bereits die Expression 
einer relativ großen Anzahl an Untereinheiten, und folglich auch Rezeptor – Subtypen, im 
Rückenmark von Ratten nahegelegt. Wir konnten im Rückenmark der Maus die Anwesenheit 
von mRNA‘s bestätigen, die für die Untereinheiten α2, α3, α4, α5, α6, β2 und β4 kodieren. 
Diese Diversität erlaubt prinzipiell eine große Anzahl an unterschiedlichen nAChR. Die 
Lokalisierung dieser Rezeptoren mit Hilfe von immunohistochemischer Färbung und 
Autoradiographie zeigte eine besonders hohe Dichte in dorsalen Bereichen der grauen 
Substanz, eine Region in der sensible Schmerzfasern synaptische Verbindungen mit 
Projektionsneuronen des Rückenmarks eingehen. Um die analgetischen und 
hyperalgetischen Eigenschaften nikotinischer Liganden einem bestimmten Typ von Rezeptor 
zuordnen zu können wurde in einem ersten Schritt die Komposition der Untereinheiten 
sowohl mit  [³H]-Epibatidin Bindungsexperimenten als auch mit einfacher und sequentieller 
Immunpräzipitation (IP) bestimmt. Die in dieser Studie verwendeten selbst hergestellten 
polyklonalen (Hasen-) Antikörper sind gegen die zytoplasmatische Schleife gerichtet und 
wurden ausgiebig an in HEK293 Zellen exprimierten, rekombinanten Rezeptoren und 
Nervengewebe von Wild-Typ (WT) und – als negative Kontrolle - Knock-Out (KO) Mäusen 
getestet. 
IP mit einer Kombination aus anti-β2 und anti-β4 Antikörpern im Rückenmark von 
C57BI/6J Mäusen ergab ein totale Konzentration von 43.7 ± 1.16 fmol/mg an 
Proteinbindungsstellen. Etwa 85% dieser Rezeptoren beinhalten die Untereinheiten α4 und 
β2, während die Assemblierung von α3 mit β4 10% aller Rezeptoren ausmachte.  Des 
Weiteren konnten wir zeigen, dass α3 auch mit β2 (in Abwesenheit von β4) Rezeptoren in 
vivo ausbildet. Die Untereinheiten α2 und α5 konnten nur in sehr kleinen (2.5% und 2%) 
aber signifikanten Mengen nachgewiesen werden während keine α6- haltigen Rezeptoren 
detektiert wurden. 
11 
 
Diese Beobachtungen wurden durch Analyse der Untereinheitkombinationen von 
Mäusen mit gezielter Gendeletion der β2 und β4 Untereinheit unterstützt. Die 
Gesamtmenge der Rezeptoren im Rückenmark von β2 KO Mäusen war auf 10% und damit 
genau auf die Menge an β4 – Rezeptoren im WT, reduziert. Trotz dieses dramatischen 
Verlustes an Rezeptoren konnten wir keinerlei Kompensation durch andere Untereinheiten 
feststellen. Im Gegensatz dazu war die absolute Anzahl an Rezeptoren in β4 KO Mäusen im 
Vergleich zum WT praktisch unverändert.  
Der Einsatz von KO – Mäusen erlaubte uns außerdem eine Berechnung der 
Bindungskinetik von [³H] – Epibatidin an definierten (aber nicht rekombinanten!) Rezeptoren 
mit Hilfe von Membranbindung. Aus diesen Untersuchungen ergab sich für den α3β4 – 
Rezeptor, analysiert in β2-KO Mäusen, ein Kd - Wert von 160 ± 24 pmol während die Affinität 
des α4β2 – Rezeptor (vorherrschend in WT-Mäusen) mit einem Kd – Wert von 53.7 ± 6 pmol 
dreimal so hoch war. 
Insgesamt gesehen zeigen unsere Beobachtungen, dass das Rückenmark in Bezug auf 
den hetero-pentameren nAChR einen sehr heterogenen Bereich darstellt was die Suche nach 
einem rein analgetisch wirkenden Liganden zu einer anspruchsvollen Aufgabe macht.     
1. Introduction 
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1. Introduction 
1.1 The nicotinic acetylcholine receptor 
The acetylcholine receptor is a pentameric membrane protein that triggers different 
events when bound by the endogenous neurotransmitter acetylcholine. There are two main 
classes of acetylcholine receptors: One of them features the muscarinic acetylcholine 
receptor, a G-protein coupled metabotropic receptor which has been named for its property 
of being activated by muscarine, a compound that can be found in certain mushrooms. The 
other class is represented by the nicotinic acetylcholine receptor (nAChR), a ligand-gated 
ion-channel, which belongs to the superfamily of Cys-loop receptors (as does the GABA-, 
Serotonin- and Glycinreceptor) and is, among other ligands, opened by the tobacco alkaloid 
nicotine. As the ionotropic nAChR is a cationic channel which can conduct K+, Na+ and Ca2+, 
its action at the neuronal synapse is excitatory. Although widely spread throughout the 
nervous system of mammals, nAChRs can also be found in different non-neuronal cells like 
endothelial cells (Macklin et al., 1998) or various cells of the immune system, lungs and 
digestive system (Wessler et al., 2003) where they are acting by regulating signalling 
mechanisms (Albuquerque et al., 2009). After the discovery of the acetylcholine receptor by 
Loewi and Dale in 1914, investigation of the nAChR was given further insight after its first 
isolation and crystallization from the electric organ (which is used to stun prey and which 
possesses a near crystalline density of nAChR) of Torpedo (Kistler and Stroud, 1981). nAChRs 
are pentamers as they are composed of five subunits which are spanning through the 
plasma membrane of a cell, closing around a central pore (Fig. 1). With an extracellular N- 
and C-terminus, each subunit is spanning four times through the plasma-membrane, 
resulting in four trans-membrane domains (TM1 – TM4) with one extracellular and two 
intracellular loops (Fowler et al., 2008).  By binding of two ligand molecules a conformational 
change opens the channel pore enabling ion flow through the plasma-membrane.  
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Figure 1: Structure of the hetero-pentameric nicotinic acetylcholine receptor: A shows how a 
subunit spans through the membrane by crossing it four times resulting in two intracellular and one 
extracellular loop. A cysteine pair close to the N-terminus of an alpha subunit creates the primary 
face of the binding pocket for nicotinic agonists. In hetero-pentameric receptors the β-subunits β2 
and β4, which lack this cysteine pair, create the complementary face of the binding site which is 
therefore located between α- and β-subunits as indicated by the arrows in B. Primary face is marked 
by +, the complementary face by -. 
  
1.2 Subunit combinations of the hetero-pentameric nAChR 
To date, there are 11 subunits identified which contribute to form different variants 
of the nAChR in neurons of mammals. Eight α-subunits: α2, α3, α4, α5, α6, α7, α9 and α10 
and 3 β-subunits: β2, β3 and β4 (McKay et al., 2007). These subunits can either form homo-
pentameric receptors by integrating five times the same α-subunit (α7-homo-pentamers are 
the most common form in the mammalian nervous system) or hetero-pentameric receptors, 
which are composed of different α- (α2-α6) and β-subunits (β2-β4) (Fig. 2). The composition 
of the nAChR greatly influences its biophysical (Sivilotti et al., 1997; Whiteaker et al., 1998; 
Lewis et al., 1997) and biochemical (Jensen et al., 2005; Kristufek et al., 1999; Xiao et al., 
1998; Parker et al., 1998) properties.   
As a consequence to the number of subunits, hetero-pentameric nAChRs can form a 
multitude of different subtypes, which are, however, also limited by certain restrictions: 
A B 
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Every hetero-pentameric nAChRs has to be composed of α- and β- subunits. Given the oddity 
that the two ligand binding sites of hetero-pentameric nAChRs are located on the interface 
between an α- and a β-subunit, the stoichiometry is restricted to either (α)2(β)3 (Deneris et 
al., 1991; Sargent, 1993) or (α)3(β)2. Additionally, the subunits α5 and β3 are known to be 
‘supplementary’ as they cannot participate in forming a binding site with a partner subunit 
and therefore can only be integrated into receptors which contain at least two further 
subunits (e.g. α4β2α5, α4β2β3).  
 
 
Figure 2: Pedigree of the acetylcholine-receptor: The neuronal type of the nAChR can form homo-
pentameres (predominantly the α7- homo-pentamere) and hetero-pentameres in regions of the CNS 
as well as the PNS. Most regions of the CNS, which includes the spinal cord, express the subtype 
α4β2 (green). 
 
Although, following the restrictions listed above, nearly all variants can be expressed 
in heterologous expression systems like oocytes and HEK-cells (Parker et al., 1998) it has 
been demonstrated that in vivo less hetero-pentameric nAChR subtypes are expressed than 
theoretically possible. This is due to the fact that specific subunits have a particular liking, 
whereas others rather avoid co-integration into a native functional hetero-pentameric 
nAChR (Gotti et al., 2006). According to this, nearly all regions of the brain are dominated by 
the α4β2 subtype (‘brain type’) whereas α3β4-receptors represent the highest frequent 
subtype in the PNS (‘ganglionic type’).     
ACh receptor 
muscarinic AChR 
nicotinic AChR 
muscle - type 
neuronal - type 
PNS 
heteropentameric 
(α3β4) 
homopentameric (α7) 
CNS 
homopentameric (α7) 
heteropentameric 
(α4β2) 
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1.3 Ligands for the hetero-pentameric nicotinic acetylcholine 
receptors 
Besides the endogenous neurotransmitter acetylcholine, a vast array of different 
plant and animal toxins target the hetero-pentameric nAChR in CNS and PNS. Additionally as 
the perspective of nAChR as potential therapeutic target arose in the last few years, a 
multitude of different synthetic ligands emerged.  
1.4 Agonists and their affinity to different hetero-pentameric nAChR 
subtypes 
Besides nicotine, epibatidine (an alkaloid found in the skin of the Ecuadorian frog 
Epipedobates tricolor) is another well documented nicotinic agonist, which binds the hetero-
pentameric nAChR with near covalent strength. Different agonists however differ in their 
affinity (Kd = dissociation constant) for the binding sites of hetero-pentameric nAChRs. The 
affinity to nicotinic agonists is an important receptor property and can be used to distinguish 
different subtypes of the hetero-pentameric nAChR. Accordingly many studies demonstrate 
that the α4β2 ‘brain-type’ binds all nicotinic agonists with higher affinity than the α3β4 
‘ganglionic type’ (Xiao et al., 1998; Perry et al., 2002) (e.g. in table 1). Especially the β-
subunit seems to play an important role for the affinity of a binding site as β2-containing 
hetero-pentameric receptors show similar affinity to agonists as well as β4-containing 
receptors. The different Kd of β4- and β2- containing receptors to nicotinic agonists can be 
exploited to differentiate them in binding methods like autoradiography. As the choice of 
the α-subunit is only sparsely affecting the Kd of nicotinic agonists for a hetero-pentameric 
nAChR, different α-combinations with the same β-subunit (like α4β2 and α6β2) cannot be 
differentiated easily with nicotinic ligands.   
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Agonist 
nAChR subtype 
α4β2* α3β4* α4β2* α3β4* 
Binding affinity Ki (nM) Functional potency EC50 (µM) 
Nicotine 0.6 - 10 290 - 476 0.35 - 5 8.1 - 110 
Epibatidine 0.042 – 0.15 20 - 240 0.0045 – 0.0085 0.024 – 0.07 
Table 1: Binding affinities and functional potencies of selected agonists for the α4β2 and the α3β4 
hetero-pentameric nAChR subtypes: The difference of the binding affinities of the two nicotinic 
agonists nicotine and epibatidine for the subtypes α3β4* and α4β2* is bigger than the difference of 
the functional potencies. The * indicates that additional subunits might be part of the receptor.   The 
data shown in the table is a collection of saturation binding experiments from different publications 
(Xiao and Kellar, 2004; Gerzanich et al., 1995; Rueter et al., 2006; Jensen et al., 2003; Marks et al., 
1996). 
 
In assays where not the binding but the opening of the channel due to binding is 
measured (like in electrophysiological methods), the functional potency (EC50 = half maximal 
effective concentration) of the agonist for the receptor subtype is important and not the Kd. 
As shown in Table 1, EC50 – differences of nicotinic agonist for β2- and β4-containing 
receptors is always smaller then differences in the binding affinity, wherefore the use of the 
former to distinguish subtypes of the hetero-pentameric nAChR in functional assays is 
limited.  
As a consequence, there is a certain lack of subtype - specific ligands. The often 
claimed selectivity of some synthetic ligands for specific subtypes of the hetero-pentameric 
nAChR has often been proven to be incomplete or conflicting (Gao et al., 2010). Therefore 
the discrimination of distinct hetero-pentameric nAChR - subtypes in nervous tissues is 
better ensued by the use of subunit – specific antibodies (AB) 
1.5 Antibodies (ABs) against subunits of the hetero-pentameric nAChR    
As the specificity of commercially available ABs has been questioned and shown to be 
insufficient (Moser et al., 2007), the working group of Dr Huck and Dr Scholze decided to 
self-create polyclonal IgG antibodies against various subunits of the heteromeric nAChR. The 
characterization of these ABs is described in detail in recent publications (Scholze et al., 
2011; David et al., 2010). All of the ABs are specific for an epitope provided on the 
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intracellular loop between the trans-membrane domains 3 and 4, as this is the most variable 
protein sequence of different α- and β-subunits.  
1.5.1 Difficulties of immunohistochemically staining nAChRs  
Although the pharmacological and biophysical profile of different hetero-pentameric 
nAChR subtypes is a detailed one, data about the morphology in different tissues is rather 
unsatisfactory. Especially immunohistochemistry (IHC) has been proven to be troublesome 
and there are several reasons for that. One is the difficult production of highly specific ABs 
against different subunits of the hetero-pentameric nAChR, which is of course the basis for 
reliable IHC. In contrast to many other proteins, receptors for neurotransmitters are 
expressed at a rather low density in the CNS. Therefore it is difficult to separate specific 
immunoreactivity of antibodies from background signal (Jones and Wonnacott, 2005). As 
mentioned above, the epitope for subunit-specific antibodies lies intracellular, wherefore 
samples have to be treated with reagents which open cell membranes, which in turn 
elevates the danger of destroying cellular structures. Finally, the only absolute reliable 
control for the specificity of an antibody is to test it on tissue where the source of specific 
protein is knocked out. As these controls exist for various other types of neurotransmitter-
controlled receptors (e.g. cannabinoid, purine and glutamate receptor) (Bridges et al., 2003; 
Mateos et al., 1998; Sim et al., 2004), reliable equivalents for the nAChR are missing (Jones 
and Wonnacott, 2005).  
1.6 Knock-Out mice for the nAChR 
Several constitutive knock-out (KO) mice for one or more subunits of the hetero-
pentameric nAChR have been bred and utilized to identify the role of specific subtypes. 
Apart from the obvious advantage of investigating the consequence of the loss of a specific 
subunit, KO-mice can also provide access to defined receptor subtypes in certain tissues. 
Superior cervical ganglia (SCG) of mice for example feature the hetero-pentameric nAChRs 
α3β4, α3β4α5 and α3β4β2 (David et al., 2010). In case of the α5β2 double KO-mouse, SCG 
only contain α3β4-receptors, which consequently allows convenient investigation of the 
properties of this subtype in vivo. Surprisingly, the phenotype for mice, which lack a highly 
frequent subunit like β4 or β2, is rather mild. 
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1.7 The spinal cord and pain 
The spinal cord is part of the CNS and processes information that is sent from the 
brain to the periphery (motoric output) and vice versa information recognized by sensory 
neurons in the periphery that is sent to the brain. The signals are conducted over spinal 
nerves, which enter/leave the spinal cord in the space between two vertebrae (foramen 
intervertebralia).  The spinal nerve is a fusion of fibres, which run in opposite directions: The 
dorsal root fibres, which contain axons of sensory neurons, whose soma lie in the dorsal root 
ganglia and which connect to the dorsal horn of the butterfly shaped grey matter. Soma of 
motor-neurons, which are located in the ventral horn of the grey matter, send their axons 
over the ventral root fibres, where they join the spinal nerve (Fig. 3). Nearly all conducted 
signals get integrated / relayed at the grey matter of the spinal cord, which, apart from 
various glia cells, also provides a multitude of different neuronal cell-types (listed in table 2). 
 
Neurons in the spinal 
cord 
Function 
motor neurons 
Their soma is located in the ventral gray matter, axons end directly 
at muscles, glands or neurons of the PNS.  
local interneurons 
Their processes are restricted to small areas of the gray matter in 
the spinal cord. They can modulate conducted sensory input and 
motoric output by inhibition via GABA. 
projection neurons 
Possess long axons and span over longer distances in the spinal 
cord. 
Table 2: Rough classification of different neurons, which can be found in the grey matter of the 
spinal cord. 
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Figure 3: Structure of the spinal cord: A shows the principal anatomical organization of the spinal 
cord. Sensory input is sent via dorsal root to the grey matter and transduced over funiculi to higher 
procession. Motoric output is sent from the brain to motor neurons which transduct the signal over 
the ventral root to the periphery.  (Illustration of the spinal cord retrieved from: 
http://www.alamo.edu/pac/faculty/lgonzales/aplabs/2401/exercises/Ex17SpinalCord,SpinalNerves,a
ndReflexes/Objective2SpinalCordMeninges.htm) 
 
Pain is the result of the activation of nociceptors, which sit at the periphery and conduct 
adequate stimuli over slow C-fibres and fast Aδ-fibres. The signal is either relayed at the 
substantia gelatinosa (the most dorsal area of the grey matter) to soma of projection 
neurons which contra-laterally send the signal to higher structures (supra-spinal) of pain-
processing (Fig. 4A), or to motor-neurons leading to direct reflex arcs in response to painful 
stimuli (spinal pain processing). 
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Figure 4: Sensory input from the periphery is caused by activation of nociceptors (pain, touch), 
mechanoreceptors (touch) and proprioceptors (positioning and movement of the body) as shown in 
A. Temperature and pain are sensed by nociceptive neurons (red) and conveyed to laminae I and II of 
the dorsal horn grey matter, where they contact soma of projection neurons, which send the signal 
to higher processions in the brain (Scheme retrieved from (Caspary and Anderson, 2003). B offers a 
view of a complete mounted murine spinal cord with still attached dorsal root ganglia (DRG). A 
dissected DRG is shown in higher magnification in C. (Photos in B and C were taken by the author) 
 
 
C 
B 
A 
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1.8 How do nAChRs influence pain-mediated pathways?  
Nicotinic agonists are known to be effective and potent analgesics. Recent clinical 
trials which aimed to benefit from this effect have not met primary endpoint, whereas 
others show efficacy but lack the therapeutic window (Gao et al., 2010). The site of action of 
this analgesic effect by nicotinic agonists is divided into spinal (Aceto et al., 1986) and supra-
spinal (processing of pain mediated pathways at the level of the brain) mechanisms. The 
former has been shown to be involved in pain processing by the circumstance that injection 
of nicotinic agonists into the spinal cord liquor (Fig. 5A) of rodents results in analgesia. This 
oddity has been supported by spinal-specific pain-tests of animals (tail-flick test, Fig. 5B) 
which have been given nicotine systemically. This effect could be observed as a reaction to 
various different nicotinic agonists, indicating, that nAChRs are involved in pain-mediated 
pathways at the spinal cord. The strongest effect, which showed the same efficacy like 
morphium with 200-fold greater potency, could be elicited with epibatidin, probably due to 
its high binding affinity for hetero-pentameric nAChR.  
 
  
Figure 5: Evidence for the involvement of spinal nAChR in pain mediated pathways:  Intrathecal 
injection of nicotinic agonists into the liquor of the spinal cord (A) provides insight into local effects 
of nAChRs. The tail-flick test (B) is believed to reflect activation of spinal reflex bows in response to 
thermal pain applied by a rod. The time and heat needed to elicit this reflex can be influenced by 
systemic and intrathecal administration of nicotine. (Source for picture A: 
http://www.stfranciscare.org/saintfrancisdoctors/cancercenter/nci/popUpDefinitions.aspx?id=CDR4
6681.xml , for B: http://www.labsupply.com.hk/Physiology%20&%20Pharmacology%20001.htm)  
 
As demonstrated with autoradiography in rats (Khan et al., 2003; Perry et al., 2002)  
nAChRs are distributed over the whole grey matter of the spinal cord, with their highest 
density in the dorsal horn. With the help of subunit specific knock-out mice, different 
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publications (Marubio et al., 1999; Matsumoto et al., 2007; Damaj et al., 1998a; Gao et al., 
2010) were able to show that not only one specific but different subtypes of the hetero-
pentameric nAChR seem to be involved in the analgetic mechanism at the level of the spinal 
cord.  
Although the involvement of spinal nAChRs in pain-mediated pathways is (especially 
due to its potential clinical benefit) of interest, the complexity of the neuronal network in 
the spinal cord offers plenty of possibilities for further participation of the nAChR in different 
other mechanisms. In contrast to nearly all other nervous regions of the CNS, the 
characterization of the spinal cord according to its occurring hetero-pentameric nAChRs has 
been surprisingly neglected thus far. The attempt of a characterization in this study is aiming 
to support the interpretation of existing and future data from functional investigations of 
spinal nAChRs. 
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2. Material & methods 
2.1 Animals  
C57/B6J WT mice and mice which lack the β2 (Picciotto et al., 1995) or the β4 (Kedmi 
et al., 2004) subunit were used for experiments in this study. None of the KO animals 
showed phenotypic differences concerning anatomy or behavior in comparison to the wild-
type. Animals were kept in thermally stable environment at 21°C in a light/dark cycle of 
10h/14h with free access to food and water. 
2.2 Preparation of the spinal cord 
For all experiments in this study, mice were in general sacrificed on day 18 (P18, 
range ± 1 day) by deep anesthesia with CO2 and subsequent decapitation. Dead animals 
were fixed dorsally on a polystyrene plate and cut open ventrally. The spine was exposed by 
removal of skin and organs followed by opening of the vertebral canal. The spinal cord was 
then completely removed without the dura mater (as dorsal root ganglia, which would have 
influenced some experiments, stick to the dura mater) under the light microscope and 
transferred on a plate with Ca2+ - free 4°C cold Ca2+ - free Tyrode’s solution (see reagents) on 
ice. 5-10 spinal cords from the same genotype were collected and transferred into an 
eppendorf tube with 1 ml Ca2+ - free 4°C cold Tyrode’s solution. After 1 minute 
centrifugation (13 000 rpm) the Tyrode’s solution was removed, the tube shock-frozen in 
liquid nitrogen and stored at -80°C. 
2.3 Membrane preparation of spinal cord tissue   
In order to homogenize spinal cord tissue, the spinal cord samples (at -80°C) were 
thawed gently on ice to approximately 4°C. 1 ml ice-cold homogenization puffer (see 
reagents) was added to 4-6 spinal cords per eppendorf tube. The tissue was dissolved by two 
ultrasonic pulses (5 sec., 30% power) of the ultrasonic homogenizer (Bandelin Sonopuls 
UW2200). The samples were cooled on ice between the pulses to avoid heat-damage. 
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Equally important was keeping the sample volume in eppendorf tubes at 500 µl and to 
correctly position the MS73 Sonotrode tip in the tube (as deep as possible in the tube 
without touching the rim) in order to avoid the formation of foam during pulsing.  
Afterwards samples were centrifuged in a Sorvall RC 6+ (20 000 g, 4°C, 30 minutes) and the 
supernatant discarded. 500µl washing puffer (see reagents) was added to each tube and 
homogenized with the ultrasonic device as described before. Afterwards samples were 
incubated on ice for 30 minutes followed by centrifugation in the Sorvall RC 6+ (20 000 g, 
4°C, 30 minutes). 
2.4 [3H]-Epibatidin membrane binding of hetero-pentameric nAChRs  
Homogenized spinal cord tissue (after membrane preparation) was re-suspended in 
TRIS Puffer (50 mM TRIS/HCl, pH=7.4). An aliquot was saved on 4°C for subsequent protein 
determination. 100 µl of the spinal cord suspension each was transferred into 24 
polystyrene tubes (Sarstedt, 5ml, 75x12 mm Ø). Each experiment was conducted in 
duplicates. An increasing gradient of Triton-labelled epibatidin ([³H]-epi) was added every 
two tubes (8 steps: 0.01/0.02/0.05/0.1/0.2/0.5/1/2 nM). Unspecific binding was determined 
by adding 300 µM nicotine 5 minutes in advance of the radioligand (although higher affine 
than nicotine, [³H]-epi is displaced from nAChR binding sites by the much higher 
concentration of nicotine) to three separate concentration steps of [³H]-epi. Each sample 
was filled up to 500 µl. This volume in combination with the receptor concentration per 
sample was experimentally determined to show no significant depletion of the radioligand 
[³H]-epi. (As epibatidin binds hetero-pentameric nAChRs with extremely high affinity, there 
is an increased risk that the desired added total concentration of [³H]-epi for a sample is not 
approximately the free [³H]-epi concentration as plenty of radioligand is immediately bound 
by nAChRs, in which case the results for the membrane binding would be incorrect (Swillens, 
1995).) All samples were incubated for 2h at room temperature followed by vacuum 
filtration over Whatman glass microfibre filters. The filters were soaked in 0.5% 
Polyethlenimine (PEI) for 30 minutes in advance to minimize unspecific binding of the 
radioligand on the filter. Filters were placed on the vacuum pump and after washing with 
ice-cold H2O, samples were filtrated. The aim was to keep pieces of membrane, which 
contain [³H]-epi bound hetero-pentameric nAChRs in the filter, whereas unbound 
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radioligand passed through (Fig. 6). Filters were separately transferred into 18 ml Sarstedt 
tubes, which contain 5 ml scintillation cocktail (Rotszint Eco Plus, ROTH).  This cocktail eluted 
the sample out of the filters and ‘translates’ radioactivity of [³H]-epi direct proportionally 
into flashes of light, which could be detected by the liquid scintillation counter.  
  
Figure 6: Radioligand, not bound to receptors on membrane pieces was washed through the filter. 
(Thanks to Michael Berger http://homepage.univie.ac.at/michael.berger/) 
 
Values were measured in decays per minute (dpm). Amount (in fmol/mg) of radioligand 
bound receptors in a sample can be calculated from specific activity of the Triton labeled 
epibatidine and the previously determined protein concentration of the membrane 
suspension. All experiments were conducted in duplicates and replicated three times 
2.5 Immunoprecipitation (IP) of hetero-pentameric nAChRs with 
subunit specific antibodies 
As dissected spinal cords are free of the dura mater, they can be dissolved directly in 
2% - Triton lysis puffer (see solutions). Two spinal cords per tube in 500 µl lysis puffer were 
pulsed for 5 seconds with the ultrasonic homogenizer (30% power) and put on ice 
immediately afterwards. Samples were then incubated on ice for 2h and subsequently 
centrifuged (16 000 g, 15 min, 4°C). The supernatant, which contained the solved nAChRs, 
was saved and the pellet discarded. An aliquot of 50 µl was taken at this point and stored at 
4°C for later protein determination. 150 µl lysate was added per sample in combination with 
7 µg subunit specific antibody in 15-20 µl 1x phosphate-buffered saline (see solutions), 1nM 
[³H]-epi and incubated on a shaker o/n at 4°C. Unspecific binding was determined in the 
presence of an excessive (compared to [³H]-epi) concentration of 300µM nicotine to half of 
the samples.  
    Direction of washing 
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Heat-killed S. aureus cells, whose membrane possesses protein A (Pansorbin, 
Calbiochem) were centrifuged (2300 g, 5 min 4°C) and washed twice with IP-High (see 
solutions), once in IP-Low (see solutions), and re-suspended in IP-Low. 20 µl of the washed 
Pansorbin was added to the samples followed by 2h of incubation on the shaker at 4°C, 
which resulted in the subunit-specific antibody binding to the receptor containing the 
subunit whereas the Fc part of the antibody was bound by Pansorbin, which increases the 
mass of the complex for centrifugation as shown in figure 7.  
 
 
Figure 7: Complex at the end of immunoprecipitation 
 
Following incubation with Pansorbin, samples were centrifuged at 2300 g for 5 min at 4°C, 
washed twice with IP-High and once with IP-Low (2300g, 1 min, 4°C) and the resulting pellets 
re-suspended in 200 µl 1 N NaOH. The suspensions were transferred into 5ml Sarstedt tubes 
containing 5 ml scintillation cocktail (Rotszint Eco Plus, ROTH) and measured in the liquid 
scintillation counter.   
2.6 Sequential immunoprecipitation (seq. IP) 
IP was performed as described above (first round of IP) until the first centrifugation 
step after 2h of incubation with pansorbin at 4°C, where the supernatant of each sample 
(which contains all of the receptors except those which were bound by the subunit-specific 
antibody) was not discarded, but transferred separately in new eppendorf tubes and put on 
ice. After that, the desired subunit-specific antibody was added to this supernatant (as 1nM 
[³H]-epi and 300µM nicotine, in half of the samples, was already present from the first IP). 
The procedure of IP (second round of IP) is then repeated as described previously. 
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The loss of protein due to the process of the first round of IP has been determined by 
comparing protein concentrations of the lysate before and after IP. Additionally, we 
determined how the procedure of the first IP influenced nAChRs, which were not 
precipitated. Protein concentration and levels of hetero-pentameric nAChR equally dropped 
to 80%. 1/5 of the result of sequential IP was therefore added to the value to compensate the 
loss of receptors in the second round (e.g. if the result for β2-containing receptors would 
result in a theoretical value of 40 fmol/mg MP in sequential IP, the real value would be 50 
fmol/mg MP) and be therefore able to compare results from IP to results from seq. IP. An 
example for sequential IP is given in figure 8. 
 
 
Figure 8: scenario of an experimental setup with seq. IP. This figure illustrates how association 
between α3- and β4 containing receptors were analyzed with the help of seq. IP. All α3-containing 
receptors are precipitated from Spinal cord lysate with the anti – α3 antibody. The supernatant, 
devoid of all α3-containing receptors is subjected to another round of IP with the anti β4 – antibody. 
Being aware of the absolute levels of β4 in the spinal cord, it is possible to calculate the amount of β4 
– containing receptors, which do and which do not contain α3 as well. 
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2.7 Statistics 
All data in Immunoprecipitation and sequential immunoprecipitation were means ± 
SEM. Data sets were analyzed by 1way ANOVA and Bonferroni’s post-test for multiple 
comparisons. Curves in membrane binding experiments were fitted to a hyperbolic curve 
based on a one-site binding model as described in (David et al., 2010). Scatchard plot 
(Rosenthal equation) was performed on binding curves to visualize one-site binding.   
2.8 Preparation of spinal cord samples for cryo-sectioning 
Spinal cords from P18 (±1 day) mice were dissected as described above. To analyze 
different levels of the spinal cord it was cut into three parts (cervical, thoracic and lumbar), 
while still residing in the spinal canal. Spinal nerve tissue above the most cervical rip was 
designated as cervical, between this rip and the most caudal rip as thoracic and beyond that 
as lumbar.  Segments were further dissected into approximately 1 cm apiece and then 
transferred separately to eppendorf tubes with 4% paraformaldehyde (PFA) and fixed for 
12h. To avoid crystallization artifacts, samples were first transferred into 1xPBS with 10% 
Sucrose o/n and then into 1xPBS with 20% Sucrose o/n. This dehydration process was 
followed by shock-freezing in -50°C isopentan (2-methylbutane) and storage at -80 °C.  
 
2.9 Coating of slides 
500 ml H2O were heated to 55°C and 2.5 g gelatin with 0.25 g chromalaun KCr (SO4)2 
* 12 H2O slowly added. After complete dissolution, the still warm chromalaun solution 
filtered and stored at -4°C. To coat, clean slides were dipped into the chromalaun solution 
and dried o/n. Coated slides were stored at room temperature. 
 
2.10 Cryo-sectioning for immunohistochemistry and autoradiography 
Samples were tempered from -80°C to – 20°C and transported to the cryomicrotome 
on dry-ice. The spinal cord tissue, chromalaun covered slides, the cryomicrotome knife and 
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the cooling cylinder (specimen holder) were cooled to -15°C in the cryomicrotome chamber. 
Single segments of the spinal cord were mounted vertically on a cooling cylinder with the 
help of Tissue- TEK and cut into 16 µm thick slices, which were, directly from the blade, thaw 
mounted on pre-cooled slides (3-4 slices per slide). The cryo-sections were either used 
immediately or stored at -20°C. 
2.11 Autoradiography 
Spinal cord sections from cervical and lumbar regions of wild-type and β2 KO mice on 
slides, freshly cut on the cryomicrotome, were dried and tempered to room temperature for 
5 minutes. The slices on the slides were encircled with a hydrophobic fat barrier using a 
Dako Pen to build an incubation room and subsequently subjected to ice-cold Tris puffer 
(see reagents) for 20 minutes at room temperature. This was followed by incubation of ice-
cold Tris puffer containing 1 nM [³H]-Epi for 2h at room temperature. To determine 
unspecific binding, 300 µM nicotine was added half of the samples. All samples were then 
washed twice with ice-cold Tris puffer for 5 seconds and once in aqua dest. for 2-3 seconds. 
Slides were then thoroughly dried with a cold fan and exposed to film in a cassette for 2 
month at room temperature in complete darkness. Standard stripes for ³H-radioactivity 
were co-incubated to get a measurement for the level of bound [³H]-epi afterwards. The film 
was developed after the incubation and dried for several hours at room temperature.   
Finally the film was digitalized by scanning with an Epson 1600 at maximal high resolution.   
2.12 Immunohistochemistry 
Spinal cord sections were thawed and dried for 5 minutes at RT and transferred to a 
water-filled moist chamber. Sections were encircled with a hydrophobic fat pen (Dako pen) 
to create an incubation space and washed three times with 1xPBS, incubated with 0.2% 
Triton in 1xPBS (20 min, RT) to permeable cell membranes (as the epitope for antbodies 
against hetero-pentameric nAChR subunits is located intracellular) and blocked with 0.2% 
Triton and 3% normal donkey serum in 1xPBS. Subsequently, the primary antibody was 
added and incubated o/n at 4°C. On the next day, samples were washed three times with 
1xPBS, followed by incubation with the secondary antibody for 1h at RT in darkness. From 
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this point, samples were kept as dark as possible to avoid bleaching of the fluorochromes. 
Slices were washed three times with 1xPBS and, if required, DAPI was added and incubated 
for 10 minutes. This was followed by another washing-step with aqua dest. and mounting 
with ProLong gold anti-fade mounting medium (Invitrogen). Samples were dried in darkness 
for 10h before regarding under the confocal fluorescence microscope (Leica TCS SP5 II).  
  
2.13 Antibodies 
2.12.1 Primary antibodies 
manufacturer antigen host dilution  type 
Millipore Map 2 (microtubuli 
associated Protein 2) 
chicken 1:1000 polyclonal 
SySy SYN (synaptophysin,  
presynaptic) 
mouse 1:200 monoclonal 
(Cy5 – 
conjugated) 
Covance SMi 31 (neurofilaments) mouse 1:1000 monoclonal 
SySy vAChT (vesicular 
acetylcholine transporter) 
rabbit 1:200 polyclonal 
Huck Lab α3 (S2)  rabbit 9.5 µg/ml polyclonal 
Huck Lab α4 (S26) rabbit 2.2 µg/ml polyclonal 
Huck Lab β2 (S19) rabbit 40 µg/ml  polyclonal 
 
2.12.2 Secondary antibodies 
manufacturer antigen host dilution fluorochrome 
Invitrogen anti-
mouse/chicken/rabbit 
goat 1:200 Alexa 568 
Invitrogen anti-
mouse/chicken/rabbit 
goat 1:200 Alexa 488 
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2.14 Solutions 
 
Ca2+-free Tyrode’s solution pH 7.4 (adjusted with 1N NaOH) 
reagent molarity 
NaCl 150 mM 
KCl 4 mM 
MgCl2 2 mM 
glucose  10 mM 
HEPES 10 mM 
 
 
10x phosphate buffered saline (PBS): pH 6.8 (adjusted with 1N NaOH) 
reagent molarity 
NaCl 140 mM 
NaH2Po4*2H2O 30 mM 
Na2HPO4 120 mM 
 
 
Tris/HCl buffer: pH 7.4 (adjusted with 1M HCL) 
reagent molarity 
Tris 50 mM 
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Homogenisation buffer: pH 7.5 (adjusted with 1N NaOH)  
reagent molarity 
HEPES 10 mM 
EDTA 1 mM 
sucrose 300 mM 
protease inhibitors (freshly added 
before use, stock at -20°C) 
concentration 
aprotinin 1 µg/ml 
leupeptin 0.5 µg/ml 
PMSF 1 mM 
pepstatin 0.5 µg/ml  
 
 
Washing buffer: pH 7.5 (adjusted with 1N NaOH)  
reagent molarity 
HEPES 10 mM 
EDTA 1 mM 
protease inhibitors (freshly added 
before use, stock at -20°C) 
concentration 
aprotinin 1 µg/ml 
leupeptin 0.5 µg/ml 
PMSF 1 mM 
pepstatin 0.5 µg/ml   
 
 
2% - Triton lysis puffer: pH 7.5 (adjusted with 1N NaOH) 
reagent molarity 
Tris 50 mM 
NaCl 150 mM 
Triton X-100 (Fluka) 2 % 
protease inhibitors (freshly added 
before use) 
 
1 tablet Roche mini complete per 10 ml 
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IP – High: pH 8.3 (adjusted with 1N NaOH)  
reagent molarity 
Tris 50 mM  
NaCl 600 mM 
EDTA 1 mM 
Triton X-100 (Fluka) 0.5 % 
 
 
IP – Low: pH 8.0 (adjusted with 1N NaOH)  
reagent molarity 
Tris 50 mM  
NaCl 150 mM 
EDTA 1 mM 
Triton X-100 (Fluka) 0.2 % 
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3. Results  
3.1 Subunit mRNA levels in the spinal cord  
nAChR are not expressed homogeneously in the CNS and the receptor frequency and 
composition of specific subunits can vary considerably within different regions. However, the 
dominant backbone subunits of the CNS are considered to be α4 and β2 (‘brain type’) in 
contrast to PNS (α3 and β4, ‘ganglionic type’). In order to determine all possible occurring 
subunits the mRNA levels of spinal cord tissue were screened by Gabi Koth and Petra Scholze 
via semi-quantitative RT-PCR (Fig. 9). They could detect transcripts coding for the subunits 
α2, α3, α4, α5, α6, β2 and β4, the strength of the signal for α5 and β4 was particularly weak. 
Figure 9: Identification of occurring subunit mRNA’s in the spinal cord indicates subunit existence 
on protein level. mRNA of different nAChR subunits was reverse transcribed into cDNA with 
Invitrogen’s ThermoScript reverse transcriptase.  Transcripts for nAChR subunits were amplified in a 
PCR reaction using subunit-specific primers as described (Putz et al., 2008). SC: RT-PCR product of 
spinal cord. +: positive control (cDNA from brain or dorsal root ganglia). -: negative control in the 
absence of template. M: molecular weight marker (100 bp ladder, Invitrogen). 
3.2 Immunoprecipitation 
nAChR subtypes are defined by their variable subunit composition. Although 
existence of mRNA is not a guarantee for translation into functional subunits, it indicates the 
possibly occurring protein products. Immunoprecipitation (IP) was carried out on [³H]-epi 
labeled, solubilized spinal cord nAChR with the according selective antibodies against those 
subunits, whose mRNA could be detected in RT-PCR. The subunit specific antibodies we used 
in this study are self-generated and extensively tested on heterologous systems (HEK293 
cells) as well as on native material from wild-type (positive control) and KO mice (negative 
control) (David et al., 2010)  [³H]-epi binds to all heteropentameric nAChR, which integrate 
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alpha- and beta-subunits regardless of their exact composition as the binding pocket for 
nicotinic agonists is created between an α- and a β-subunit  (Xiao et al., 1998; Xiao and 
Kellar, 2004). As β3 is an accessory subunit only (and RT-PCR revealed that β3 is not 
occurring in the spinal cord), every receptor contains at least a β2, a β4 or both subunits. As 
a consequence, nAChR precipitated with a conjunction of antibodies against β2 and β4 
resemble the absolute number of receptors that can be found in the spinal cord. We 
exploited this rational by using the result of IP with a mix of anti-β4 and anti-β2 ABs 
together, as the 100% reference (Fig 2A). Consequently, the use of either anti – β4 or anti – 
β2 will suffice to precipitate all heteromeric nAChR in β2 and β4 KO animals. 
3.2.1 Wild – type nAChR in the spinal cord are fairly heterogenous / What we 
learn from the frequency of subunits as determined by IP. 
 IP with a combination of anti- β2 and anti-β4 AB on the same sample determined the 
absolute number of hetero-pentameric nAChR in the spinal cord at 43.7 ± 1.16 fmol / mg 
membrane-protein (MP). It has been demonstrated in previous studies (Piciotto 2002; Gotti 
et al 2005; Turner and Kellar 2005) that α4 and β2 are the dominant CNS nAChR subunits 
according to frequency, forming the CNS backbone receptor α4β2 (‘brain type’). I could 
confirm this by IP on spinal cord tissue, where the antibody against β2 precipitated 85%, 
whereas α4-containing receptors could be found in 87% of all heteromeric nAChR (Fig. 10A). 
α3 (18%) and β4 (10%), the backbone subunits of the PNS, showed significantly lower levels 
in the wild-type spinal cord. α2 (2.5%) and α5 (2%) gave only very little contribution to the 
number of hetero-pentameric nAChR, but still significantly more than zero, whereas α6 
could not be detected. The results of IP show that neither α4 nor β2 reached the level of 
100%. Consequently, neither α4 nor β2 can be found in every nAChR in the spinal cord. 
However, this fact raised the question whether in any case one of the two subunits is 
present in every spinal cord receptor. To resolve this I set up an IP to compare the absolute 
number of nAChR (β2 + β4) with the amount of receptors, which could be precipitated with 
a combination of our antibodies against α4 and β2 (α4+β2) (Fig. 10B). This experimental 
setup showed that 91% of receptors, significantly less than 100%, contain either α4, β2 or 
both subunits in one nAChR. The fact that these two antibodies could precipitate 85 and 87% 
on their own demonstrates that a majority of α4 and β2 are always assembled in one 
pentamer, whereas only a minority of nAChR can be found, where these two subunits are 
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separated (~5%). Furthermore, the results give evidence, that the remaining ~10% of overall 
receptors which neither contain an α4 nor a β2 - subunit have to be composed of α3 and β4.  
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Figure 10: α4 and β2 dominate nAChR-numbers, but they are not ubiquitous: Absolute numbers of 
nAChR, which contain specific subunits in fmol/mg membrane protein from wild-type spinal cord as 
determined by immunoprecipitation. Spinal cord was removed from P18 wild-type mice and nAChR 
from the tissue solubilized in Triton-Lysispuffer. All nAChR were labeled with [³H]-epi (1nM) followed 
by addition of a specific antibody, indicated on the abscissa. Non-specific Binding was measured by 
adding excessive nicotine (300µM) and subtracted from the total value to receive specific binding of 
[³H]-epi . The number of precipitated receptors was measured in fmol and related to protein levels of 
the samples in mg.  A: Comparison of different amounts of receptors precipitated with specific 
subunits. As β2 and β4 are the only β subunits in the spinal cord, the β2+β4 column represents the 
amount of all hetero-pentameric (consisting of α and β – subunits) nAChR in the spinal cord at 43.7 ± 
1.16 fmol / mg MP. B: Evidence for the existence of hetero-pentameric nAChR in the spinal cord 
devoid of α4 and β2 (=10% α3β4*). Data are the mean ± S. E. M. of 6 experiments (A) respectively 3 
experiments (B) *, p <0.05; **, p<0.01 statistical significance between columns was analyzed with 
1way ANOVA and Bonferroni’s post-test 
 
Although IP revealed the absolute contribution of single subunits occurring in the spinal cord 
of mice, the degree to which certain subunits are associated with each other cannot be 
resolved with this technique. 
3.2.2 Association of subunits in the wild-type spinal cord  
To further resolve the hetero-pentameric nAChR of the spinal cord I additionally 
performed sequential IP. This technique allows analysis of nAChR that are left behind after 
all receptors which contain a specific subunit are removed. It therefore gives insight into 
whether two subunits are co-expressed in a receptor or not (Flores et al., 1992; Hernandez 
et al., 2004). The rational of this particular experimental setup is that you perform an IP (first 
A B 
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round) with a specific antibody (clearing AB). After the removal of all receptors which could 
be precipitated in this first round you perform a second IP (second round) with a different 
AB (capturing AB) on the nAChR remaining in the sample after the first round. If the 
capturing AB, specific for subunit 1, is not detecting significant levels of subunit 1-containing 
receptors, the clearing AB, specific for subunit 2, was able to remove all nAChR’s which are 
associated with this hypothetic subunit 1. The consequence is that subunit 1 and 2 can only 
be found together in one receptor and never separated. Vice versa in a case where the 
subunit 1 specific capturing AB detects 100% of receptors (which is the same amount that 
you would detect in conventional IP with this AB), removal of subunit 2 – containing nAChR 
in the first round by the subunit 2 – specific clearing AB, didn’t remove subunit 1 – 
containing receptors. Therefore subunit 1 and subunit 2 are never associated in the same 
hetero-pentameric nAChR. However, in most cases I didn’t retrieve all - or - nothing results, 
but merely situations where two subunit were only associated to a certain percentage. To 
proof the reliability of the test system I performed negative control, where the clearing and 
capturing AB where one and the same. In this case the clearing AB was able to remove all 
nAChR which contained the corresponding subunit, whereas the capturing AB showed no 
signal. As a positive control the antibody against α6 (which is not expressed in the spinal 
cord) has been used as clearing AB. With β2 + β4 as capturing AB, I was then able to detect 
similar levels of signal as with β2 + β4 in conventional immunoprecipitation (data not 
shown). In my first test row I tried to prove the existence of non α4- and β2 – containing 
receptors (~10 % were predicted from the results of IP as described earlier). This could be 
fulfilled by sequentially precipitating receptors with α3 as capturing AB, which could not be 
precipitated with α4 and β2 as clearing AB’s (Fig. 11A). When I removed those nAChR that 
contain α4 and β2 in the first round, the antibody against α3 could still identify 5% of total 
heteromeric nAChR as α3-containing receptors in the second round, which are not 
associated with either α4 or β2. As a negative control sequential immunoprecipitation with 
α3 as capturing AB was performed on samples which were cleared of all nAChR by using a 
combination of our antibodies against β2 and β4 as clearing ABs. As the latter two are 
precipitating all possible hetero-pentameric nAChR in the spinal cord, none should be left for 
further precipitation with other antibodies as turned out to be the case. As previously 
discussed every hetero-pentameric nAChR is comprised of α- and β subunits, therefore the 
receptors precipitated with α3 in this experiment that do not contain α4 and β2 have to 
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contain β4, which is the only β- subunit of the mouse spinal cord except β2. Therefore 5 % of 
all nAChR in the spinal cord are α3β4 containing receptors, which are not associated to α4 
and β2.  
In order to resolve all associations of nAChR I did extensive analysis of α3 and β4 with 
the help of further sequential IP and screened to which amount the α3β4 subtype is 
associated with the dominant subunits α4 and β2, with the minor frequent α5 and α2 and 
with each other. The rationale behind choosing α3 and β4 as capturing ABs in this 
experimental setup is that the receptor number of these two subunits is in a range (α3 18%, 
β4 10%) where results of sequential IP can be interpreted more clearly and provide more 
information as it would be the case with the huge number of α4- and β2-, or the small 
number of α5- and α2- subunits containing receptors.      
3.2.3 β4 - associations of nAChR 
In the first series of sequential IP I used β4 as the capturing AB (Fig. 11B) on samples 
which where pre-cleared separately with different clearing antibodies against the subunits 
β2, α2, α3, α4 and α5. The combination of anti-β2 and anti-β4 and the anti-β4 alone as 
clearing ABs were done as negative control because no β4-containing receptor should be left 
in those samples after the first round of sequential IP. Consequently the capturing AB 
against β4 did not detect any receptors in those cases. Setting up seq. IP with anti-α6 as 
clearing AB would not remove any nAChR’s from samples in the first round (α6 is not 
expressed in the spinal cord, Fig. 10A) and could be used as positive control. The number of 
receptors, which could be found in those samples with our AB against β4, therefore 
represents the number of all β4- containing receptors of the spinal cord, the 100% value of 
this particular test series. 100% of nAChR which contain a β4 subunit are 10 % of all 
heteromeric nAChR (Fig. 10A). Concerning associations of β4 with α3, we could show that 
pre-clearing samples with α3 also removed all β4- containing receptors in the first round of 
sequential IP, as β4 does not capture any nAChR in those samples in the second round. This 
result demonstrates that every β4-containing receptor in the spinal cord (10% of total 
receptors) is an α3β4* receptor (The asterisk indicates that this composition can contain 
additional subunits). When I used α2 and α5 as clearing ABs, the amount of nAChR, which 
could be precipitated with β4 as capturing AB was as high as in samples pre-cleared with the 
AB against α6, which does not occur in the spinal cord. This would mean that α5 and α2 are 
never associated with β4. However, it may also be possible that the number of nAChR, 
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where β4 are associated with α5 or α2 is below the level of the detection system, as these 
two subunits can only be found to a marginal degree in the spinal cord (Fig. 10A)  
Concerning the issue of how the highly frequent α4 and β2 are associated to the 
α3β4 receptor, removal of α4-containing nAChR decreased the amount of all β4-receptors 
(100% β4 receptors = 10% of all receptors, Fig 10A) to 70% (Fig 11B) which means that the 
30% of α3β4 receptors, which are lost in the first round of sequential IP are associated with 
α4 (α3β4α4).  Similarly, removing β2-containing receptors in the first round of sequential 
immunoprecipitation left 60% of β4-receptors in the supernatant. Therefore the other 40% 
of α3β4 receptors is associated with β2 (α3β4β2). Of course it is also possible that α4 and β2 
are associated with α3β4 to a certain degree forming the complex α3β4a4β2 subtype. As this 
cannot be completely resolved I deduce 5% pure α3β4 and 5% α3β4* with possible 
additional α4 or/and β2 – subunits (= α3β4α4/α3β4β2/α3β4α4β2). 
When pinpointing at percentages of receptor combinations by bringing together 
results of different experimental setups, it appears more convenient to rather stay in a 
resolution of 5% steps than trying to assume the exact percentage. Additionally it might also 
be possible that the receptor composition is exposed to slight variation depending on the 
individual mouse. However, in agreement with experimental results, the possible receptor 
distribution thus far concerning α4, β2, α3 and β4 would be: 5% α3β4; 5% 
α3β4α4/α3β4β2/α3β4α4β2; 10% α4β2α3*/α3β2*; 80% α4β2*. The asterisks indicate a 
possible additional α5 and/or α2 –subunit assuming that these two subunits prefer to 
assemble with the α4β2* combination.   
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Figure 11: Sequential Immunoprecipitation reveals possible nAChR – subtypes in the wild-type 
spinal cord.  [3H] – epi labeled spinal cord extracts of P18 wild-type mice were immunoprecipitated 
with a clearing AB. Receptors, which could be precipitated in this first round were removed by 
centrifugation. nAChR remaining in the supernatants were precipitated in a second round with a 
different (capturing) AB. The bars demonstrate the amount of [3H] – epi labeled receptors caught 
with the capturing AB. The subunits on the x-axis indicate the specificity of clearing and capturing 
AB’s. β2+β4 represents a combination of AB’s against these two subunits, used together on one 
sample. As these two represent all possible β-subunits in the spinal cord, a combination of clearing 
AB against them always captures all hetero-pentameric receptors in the first round of sequential IP, 
serving as negative control. A: Evidence for existence of the α3β4 nAChR subtype, devoid of α4 and 
β2. Samples were either pre-cleared from all nAChR (β2+β4) or from receptors containing β2+α4, β2, 
or α4. Additionally the evidence for receptors where α4 and β2 are separated is demonstrated, as 
clearing with one of these two left ~5% of the other one and vice versa. Bars represent either α3, α4 
or β2 containing receptors, remaining after the first round of sequential IP. The percentage of 
receptors is relative to the overall number of all hetero-pentameric nAChR from single IP. B: 
Associations of β4 to all other subunits, which occur in the wild-type spinal cord. Bars represent the 
percentage of nAChR immunoprecipitated with our AB against β4, relative to all β4 – containing 
receptors. The amount of percentage denotes the number of receptors that are not associated to a 
specific clearing AB, represented by a corresponding bar. α6 doesn’t occur in the spinal cord and 
designates the 100% value of all β4 receptors in this experiment. Note that α3 removes all β4-
containing receptors in the first round of sequential IP C: Associations of α3. Experimental setup and 
table are identical to sequential IP described in 3B. AB’s against α4 and β2 reduce α3 levels to 45% 
and 40%, indicating that ~half of all α3 containing receptors assemble to form α4β2α3.  Data are the 
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mean ± SEM of three independent experiments. Statistical differences between bars were indicated 
by 1way ANOVA and Bonferroni’s post-test.  
3.2.4 α3 - associations of nAChR 
After revealing the associations of β4 with other subunits of nAChR I set up 
sequential immunoprecipitation with the AB against the subunit α3 as the capturing AB and 
different clearing ABs. As a negative control, α3 could not detect significant levels of α3-
containing nAChRs in samples, which were pre-cleared with either a combination of β2 plus 
β4 or α3 itself. By using the AB against α6, which doesn’t occur in the spinal cord, as the 
clearing AB, all nAChR were left in the sample after the first round. The amount of receptors 
precipitated with α3 as capturing AB in the second round was therefore referred to as our 
100% value in this test row. 100% of receptors, which contain α3 are equivalent to ~20% of 
all nAChR (Fig. 10A).  
Pre-clearing samples with antibodies against α2 and α5 in the first round of 
sequential IP did not affect the amount of α3 – containing nAChR, which could be 
precipitated in the second round. As we already observed in combination with the β4 
subunit, α2 and α5 show no association to α3 as well. That means that in spinal cord nAChR 
α2 only forms either α2β2 or α2α4β2, whereas α5, which is only an accessory subunit 
(introduction), can only be found in α4β2 receptors. 
As a consequence to my earlier statements, that every β4-containing receptor 
contains α3 and that the amount of α3 (~20% of total receptors) doubles the amount of β4 
(~10% of total receptors), half of all α3-containing receptors are α3β4*. This is reflected in 
the result that pre-clearance with β4 left 50% α3-containing receptors in the supernatant 
(Fig. 11C). Furthermore, if one half of all α3 assembles with β4 to form heteromeric nAChR, 
the other half has to be associated with β2, the only remaining β-subunit in the spinal cord 
next to β4. Subsequently, samples treated with β2 as capturing AB left 40% α3-containing 
receptors. We could find similar results when pre-clearing samples with our antibody against 
α4 in the first round, leaving behind 45% of receptors, which could be precipitated with α3 
as capturing AB. However, the fact that α4 and β2 are almost always co-assemble in one 
receptor (Fig 10B), doesn’t necessarily mean that those α3 subunits, which are not 
associated with β4 are in any case α3α4β2 receptors.  In the rare population of receptors, 
where β2 is separated from α4 (Fig 10B), α3 is the only reasonable α-subunit (by means of 
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frequency) which can assemble with β2 (α2 might be possible, but its frequency is very low, 
α5 is only an accessory subunit) forming α3β2* receptors.  
In consensus with our results from investigation of the wild-type nAChR with the help 
of IP and sequential IP I propose the following receptor distribution in the spinal cord: 5% 
α3β4; 5% α3β4α4/α3β4β2/α3β4α4β2; 10% α4β2α3/α3β2; 75% α4β2; 2,5% α2β2/α2α4β2 
and 2% α5α4β2. Note the absence of any asterisks.     
3.3 Lessons from KO-mice 
Originally we utilized the β2- and β4 KO mice to adequately test the specificity of our 
self-generated ABs, however, there are also some interesting aspects about how the 
distribution of nAChR-subtypes changes when a particular subunit is missing. The idea of 
analyzing nAChR in KO-mice with IP is originating from two general questions: 1) Is there any 
compensation for the loss of one subunit by others? 2) Can I observe any preferences of 
certain subunits to co-assemble together in one receptor?  
3.3.1 β4 KO 
According to the results from wild-type animals, knocking out the β4 subunit was 
expected to show less impact then knocking out β2, as β4 only occurs in 10% of hetero-
pentameric receptors. Due to the lack of β4, every hetero-pentameric nAChR in β4 KO mice 
contains the only remaining β-subunit β2.  Therefore, Immunoprecipitation with anti-β2 
revealed the total number of receptors (42 ± 2.7 fmol / mg MP, Fig. 12A), which was not 
significantly different from the overall amount of nAChR in the wild-type (represented by IP 
against β2 and β4: 43.7 ± 1.16 fmol / mg MP, Fig 10A). Hence, the overall frequency of 
receptors is equal in these two genotypes. However, β2-containing receptors of animals 
lacking β4 turned out to be slightly increased in comparison to wild-type animals (37.5 ± 
5.14). It might therefore be possible that knocking out β4 resulted in a slight up-regulation of 
β2 for means of compensation. However, this result should be considered with care as the 
difference might be just below the range of where our testing system is reliable.  
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Figure 12: Number of nAChR in β4–KO is equal to wild-type receptors, but drops to 10% in β2-KO 
mice. Figures show the absolute numbers of nAChR, which contain specific subunits in fmol/mg 
membrane protein from β2 KO and β4 KO spinal cord tissue as determined by immunoprecipitation. 
Spinal cord was removed from mice of the two genotypes and nAChR from the tissue solubilized in 
Triton-Lysispuffer. All nAChR were labeled with [³H]-epi (1nM) followed by addition of a specific 
antibody, indicated on the abscissa. Non-specific Binding was measured by adding excessive nicotine 
(300µM) and subtracted from the total value to receive specific binding of [³H]-epi. The number of 
precipitated receptors is demonstrated in fmol and related to protein levels of the samples in mg.  
Data are the mean ± SEM of three independent experiments. A: Comparison of the absolute numbers 
of hetero-pentemeric nAChRs in wild-type, β4 KO and β2 KO. Bars represent the 100% value of 
receptors which could be precipitated with anti-β2 + anti-β4 in wild-type, anti-β2 in β4 KO and anti-
β4 in β2 KO. B: IP on spinal cord tissue from mice with distinct deletion of β4. Bars represent the 
amount of receptors, which contain the specific subunit marked on the x-axis.  100% value refers to 
receptors precipitated with β2, the only remaining subunit in this genotype. Level of α4 is 
significantly lower than β2, concluding that β2 also assembles to form α2β2 and α3β2 next to the 
major α4β2 C:  IP on spinal cord tissue from β2 – KO mice. Bars represent the amount of receptors, 
which contain the specific subunit marked on the x-axis. 100% value refers to receptors precipitated 
with β4, the only remaining subunit in this genotype. 70% of receptors form the α3β4 – subtype, 
whereas 30% contain an additionally α4 to compose α3β4α4. Levels of α2 and α5 could only be 
found in traces (0.2 fmol/mg MP), which are below the resolution of our detection system in terms of 
significance. Statistical differences between columns were indicated by 1way ANOVA and 
Bonferroni’s post-test. *, p <0.05; ***, p<0.0005 
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The anti-α4 antibody precipitated ~90% of all receptors, leaving 10% of β2 – 
receptors which lack α4. These 10% most likely form 4% of the α3β2- and 2.5% of the α2β2-
subtype. The fact that the sum of α-subunits does not quite reach the level of β2 indicates 
that the detection range of IP is limited to a certain degree. However, the strong reduction 
of α3 from 18% in the wild-type to 4% in the β4 KO underlines the preference of this subunit 
to assemble with β4 rather than with β2. The frequency of α5 - subunit in β4 KO mice was 
unaffected by the lack of β4 which underlines the statement from initial experiments that α5 
has a liking to integrate with α4β2 to form α4β2α5 receptors. This is in keeping with several 
studies which also report the existence of this particular subtype in various other CNS-
regions (Conroy and Berg 1998; Gerzanich et al. 1998; Mao et al. 2008). Similarly to α5, the 
level of α2-containing receptors was not affected in the β4 KO, resulting in 2.5% of total 
receptors, whereas α6 could not be detected. 
 Summarized, my findings in the β4 KO indicate 90% α4β2*, 4% α3β2* and 2.5% 
α2β2*. The asterisks indicate that all these compositions may contain an additional α5 
subunit, although by sheer numbers, the probability for α5 integration into the α4β2α5 
subtype is of course high. 
3.3.2 β2 KO 
IP on spinal cord of β2 KO mice yielded striking differences of general nAChR 
expression as the overall number of receptors, determined by IP with AB against β4, resulted 
in 4.5 ± 0.51 fmol/mg MP (Fig. 12B), revealing a tenfold reduction of heter-opentameric 
receptors compared to the wild-type (43.7 ± 1.16 fmol / mg MP). At a closer look it becomes 
obvious that the receptors are leveled to match the amount of β4 (the only remaining β 
subunit of hetero-pentameric nAChR in this genotype) at ~4 fmol/mg MP. This is the same 
amount of β4 as observed in the wild-type (Fig 10A) demonstrating that the expression of β4 
is not affected at all by the lack of β2.  
The amount of α3, the preferred α-subunit partner of β4, adjusts to the available β-
containing receptors resulting in the fact that all nAChR of β2 KO are α3β4*-receptors. The 
number of α4 containing receptors drops dramatically to ~1 fmol/mg MP (from nearly 40 
fmol/mg MP in the wild-type), assembling with α3β4 to form the α3β4α4 subtype. This 
experiment proofs the ability of neurons to express this composition in vivo, about which we 
already speculated from results of initial experiments in WT IP and sequential IP (Fig. 11B 
and 11C). α5 and α2- containing receptors seem to be increased in the β2 –KO (6% and 5%) 
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in comparison to 2 and 2.5% in the wild-type. However, as the percentage is relative to the 
absolute number of receptors in each genotype, 2% and 2.5% of these two subunits make up 
to ~1 fmol/mg MP in the wild-type, whereas 5 and 6% resemble ~0.2 fmol/mg MP in the β2-
KO, which is by high chance below the range of our detection system. Therefore these 
results rather back up the hypothesis, that α5 and α2 have a preference for α4β2- than 
α3β4-containing receptors in the spinal cord. As observed in the wild-type and the β4 KO 
also β2 KO provided no detectable amounts of α6.  
Results of IP suggest only two subtypes of hetero-pentameric nAChRs in the spinal 
cord of β2KO mice: 70% α3β4 and 30% α3β4α4. Keep in mind that the overall number of 
heteromeric nAChRs is reduced to 10% (compared to wild-type and β4 KO) in this genotype.     
3.4 Membrane Binding of [³H]-epibtidine reveals three times higher 
affinity of α3β4* compared to α4β2* receptors 
 Kinetics of nAChR have been investigated in defined compositions of heterologous 
systems (Parker et al., 1998; Perry et al., 2002) as well as in native tissues from various 
regions of the nervous system (Champtiaux et al, David et al.) In our study we use the 
advantage of defined receptor compositions in the native spinal cord tissue of wild-type 
(dominant α4β2) and β2 KO (dominant α3β4) mice to distinguish binding site pharmacology.  
 At first we determined kinetics of [³H]-epi -binding to spinal cord membrane 
homogenates of wild-type animals. The binding was saturable with a dissociation constant 
(Kd) of ~54 pmol and a maximum binding capacity (Bmax) of ~70 fmol/mg MP. As we showed 
in this study in initial experiments, ~80% of receptors in the wild-type spinal cord are 
composed of α4β2. Therefore the affinity of wild-type nAChR to [³H]-epi is represented by 
this subtype. The contribution of other receptor subtypes in the wild-type, if different in 
their kinetic properties, could not be shown as their contribution is relatively low. This was 
supported by analysis of the membrane binding data as the fitting of our data points by non-
linear regression was better suited for one than multiple binding sites determined with 
Graph Pad Prism version 4.0. To visualize this we transformed the curve to Scatchard blot.  
Kinetics of [³H]epi binding to spinal cord tissue of β2 KO mice yielded a three times 
higher Kd of ~160 pmol in comparison to wild-type tissue. As we could show by IP, this 
genotype produces α3β4* only, therefore binding analysis in mice lacking β2 represents the 
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affinity of this composition for [³H]epi. Bmax value of ~ 7.7 fmol/mg MP showed an 
approximately tenfold reduction of overall nAChR in the β2 KO in contrast to wild-type, 
which we could also detect by IP. The difference of absolute numbers of receptors between 
the two techniques is a result of the different spinal cord tissue pre-processing. Membranes 
are prepared for membrane binding experiments, a procedure where cytosolic proteins are 
lost, which is not the case in IP experiments. 
0.0 0.5 1.0 1.5 2.0
0
20
40
60
80
100
nM epibatidine
[³
H
]-
ep
ib
at
id
in
e 
bi
nd
in
g
fm
ol
/m
g 
m
em
br
an
ep
ro
te
in
0.0 0.5 1.0 1.5 2.0
0
2
4
6
8
10
nM epibatidine
[³H
]-e
pi
ba
tid
in
e 
bi
nd
in
g
fm
ol
/m
g 
 m
em
br
an
ep
ro
te
in
0 20 40 60 80
0
500
1000
1500
Bound
B
ou
nd
/F
re
e
0 2 4 6 8
0
20
40
60
Bound
B
ou
nd
/fr
ee
A B
 
Figure 13: α4β2* have a three times higher affinity to [³H]-epi than α3β4* in native tissue. 
Membrane binding of (A) wild type (Bmax= 69.92 ± 1.75 fmol/mg MP, Kd= 53.67 ± 5.9 pmol) and (B) 
β2 KO (Bmax= 7.73 ± 0.33 fmol/mg MP, Kd= 160.02 ± 24.3 pmol) spinal cord tissue with according 
Scatchard plot transformation. Wild-type tissue was homogenized by membrane preparation and 
incubated with 12 different [³H]-epi concentrations (0.01 – 2 nM) in sample volumes of 0.5 ml for 2h 
at RT and separated by centrifugation. Note the different slope between the two curves indicating 
the different affinity and the tenfold reduction of receptors in the β2KO.  Data are the mean ± SEM of 
three independent experiments.  
3.5 Localization of specific nAChR subunits in the spinal cord 
Besides frequency and properties of specific nAChR subtypes in the spinal cord, their 
distinct function and involvement in specific processes is undoubtedly of major interest. 
Therefore my next task was to determine localization of different receptor compositions 
within the wild-type spinal cord to finally be able to assign them to spinal mechanisms as 
there is detailed information about regional anatomical structures and their function  
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3.6 Autoradiography   
In situ localization of nicotinic agonist binding sites in spinal cord regions was done by 
incubating spinal cord slices with 1nM [³H]epi (As we learned from membrane binding 
experiments in this study that this concentration is sufficient to saturate all hetero-
pentameric nAChR subtypes) and exposing tissue with bound radioligand to film. We chose 
the α4β2* subtype dominated wild-type and β2 KO, where all nAChR contain α3β4* to 
distinguish localization between these two compositions. Additionally we tested for 
differences between lumbar and thoracic areas as distribution of receptors subtypes might 
vary depending on the axial position in spinal cord. Initial IP experiments on spinal cord 
tissue of separated lumbar and thoracic regions did not yield different results according to 
receptor frequency (data not shown). However, as we could find [³H]epi binding 
concentrated in regions of the dorsal horn and dorsal to the central canal (Fig. 14), this was 
true for thoracic as well as lumbar sections. The lesser binding of nicotinic agonist to β2 KO 
slices was expected given the fact that this genotype contains only a tenth of nAChR (in 
contrast to the wild-type). However, although definitely [³H]epi bound receptors were visible 
in this genotype in comparison to negative control, the weakness of the signal prevented 
assignment to a specific area.     
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Figure 14: High density of nAChR in the dorsal horn region of the spinal cord Autoradiograms 
display [³H]epi binding to wild-type thoracic (A), wild-type lumbar (B) and β2 KO lumbar (D) spinal 
cord sections. 16 µm thick slices were cut on a kryotome, mounted on glass slides 4-5 apiece and 
incubated with 1nM [³H]epi. Detection for unspecific binding was done by parallel addition of 300µM 
nicotine and neither showed any signal in wild-type lumbar (C) nor β2 KO thoracic (E) slices. Slices 
were air – dried and exposed to film for 2 month. Black rectangular squares narrow the area where 
single slices (tagged with red arrows) showed impact on the film. Additional slices were dyed 
immunocytochemically with an AB against MAP2 to visualize the entire grey matter in more detail 
(F). Note that magnified slices of wild-type thoracic region (G) and wild-type lumbar region (H) show 
stronger [³H]epi binding in the dorsal and central area of the spinal cord. As [³H]epi binding to β2 KO 
slices was barely visible, magnifying autoradiograms of this genotype revealed no details.   
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3.7 Immunohistochemistry  
Staining of nAChR subunits has been performed on different tissues in rat and mouse 
(Gahring and Rogers, 2008; Khan et al., 2003). Still, there is not much known about exact 
receptor targeting and assembly of distinct nAChR subunits on the various types of neurons 
in the spinal cord.  
3.7.1 Various markers against spinal cord neurons  
In order to restrict nAChR to cellular morphological structures we immunolabelled 
spinal cord cryosections with different antibody markers additionally to our subunit specific 
polyclonal AB’s. The grey matter of the spinal cord could be visualized with an AB (Millipore, 
polyclonal) against MAP2 (Microtubule Associated Protein 2), a cross-linker of microtubule 
(MT) in dendrites and cell bodies of neurons. This AB revealed the classic H-shaped or 
butterfly outline of the grey matter (Fig. 15). Confirming this, staining with an AB (Covance, 
monoclonal) against pan-neuronal neurofilaments provided similar results. However, as the 
grey matter of the spinal cord is packed with cell bodies of various types of neurons, these 
two markers give no insight into detailed cellular morphology. This high density of neurons 
logically produces an enormous amount of synaptic connections between somas and 
dendrites. Co-staining with AB’s against the vesicular acetylcholine transporter (vAChT, SYSY, 
polyclonal) and synaptophysin (SYN, SYSY, monoclonal) indicated presynaptic sites of 
potentially cholinergic nerve terminals. vAChT showed great distribution all over the spinal 
cord and could not be restricted to a defined area or lamina. However, especially the outline 
of motorneurons, by far the biggest sized cells in the spinal cord, in the ventral horn could be 
identified to contain cholinergic varicosities which showed nice co-localization with 
synaptophysin.  
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Figure 15: Different markers reveal morphology of the spinal cord and its synaptic varicosities. 
Photos depict immunofluorescence of 4% PFA post-fixed 16 µm thick thoracic spinal cord 
cryosections from P18 wild-type mice incubated with primary and secondary AB A: Visualization of 
the characteristic H-shaped grey matter of the spinal cord with anti-microtubule associated protein 2 
(MAP2) AB coupled with red fluorescence secondary AB (Alexa 568). B: Higher magnification of MAP 
2 signal from left ventral horn shows the neuropil of the grey matter. C: Similar signal in the ventral 
horn was retrieved by staining with AB against pan-neuronal neurofilaments (SMi31). D, E, F show 
co-staining of ventral region with AB against vesicular acetylcholine transporter (vAChT, green) and 
synaptophysin (SYN, red). Note that the characteristic outlines of motorneurons are visualized by 
vAChT. G, H, I depict a motorneuron in higher magnification co-stained with vAChT (green) and SYN 
(red). Note that vAChT could only be found on varicosities around the motorneuron, whereas SYN 
additionally marked presynaptic terminals of smaller, most likely interneurons around the 
motorneuron. Yellow areas in the merged picture show clear co-localization of the two markers. 
Photomicrographs on this Figure and in Figures 8-10 depict one representative of a minimum of 
three separate experiments. 
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3.7.2 Immunohistochemical labeling of nAChR subunits      
Immunohistochemical stainings of wild-type spinal cord cryosections with our self-
produced AB’s against the α3, α4 and β2 nAChR-subunits showed enhanced nAChR density 
in the dorsal horn, confirming our results from autoradiography. Since anti-α4 provided 
constantly strong signal in IHC, we utilized this AB as our reference for further stainings with 
other anti-nAChR subunit AB’s. Fig. 16 shows that the frequency of α4 positive neurons 
faded form dorsal, central to ventral, whereas the density of overall cells, as marked by 
DAPI, was constant.  In agreement with studies where IHC was performed on nAChR in 
various neuronal tissues (Dehkordi et al., 2007; Duncan et al., 2008; Picciotto et al., 2000) we 
observed that especially cytoplasm of nAChR positive neurons could be stained with our 
anti-nAChR AB’s. Higher magnification of α4 positive cells in dorsal regions of the spinal cord 
reveals this strong intracellular staining of some small diameter interneurons (Fig. 17). Co-
staining of α4 and synaptophysin showed only very little co-localization on the extracellular 
surface of these interneurons. Analysis was particularly difficult as due to their small size 
details of those cells were limited by the highest possible resolution of our confocal 
fluorescence microscope. However, we could identify interneurons with synaptophysin, 
which lack signal of α4, indicating that nAChR are not ubiquitously expressed in all 
interneurons. Higher magnification of ventral regions provided additionally signal from 
characteristically bigger sized motorneurons. Although we could show vAChT in varicosities 
around motorneurons in initial stainings, the α4 signal was interestingly restricted to cellular 
compartments around the nucleus. Unfortunately, DAPI was not prone to infiltrate 
motorneurons and mark nuclei of these big cells, although the staining of nuclei from smaller 
cells was flawless.  
Fig. 18 shows immunolabeling for antibodies against α4, α3 and β2 in wild-type and 
different KO mice.  As for the remaining subunits which occur in the spinal cord according to 
our results from IP, anti - β4 showed unspecific signal (data not shown), whereas no signal 
could be detected with AB’s against the minor frequent α2 and α5 subunit. The observed 
strong α4 signal in wild-type and β4 KO mice, goes in agreement with results from IP, which 
provided high frequency of α4-containing nAChR in these two genotypes (85% in wild-type, 
91% in β4 KO). In mice lacking β2, the signal was generally diminished, fitting into the 
scheme that α4 is drastically reduced in this genotype when compared to wild-type and  
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Figure 16: nAChR’s density gradually decreases from dorsal to ventral. Photos depict 
immunofluorescence of 4% PFA post-fixed 16 µm thick thoracic spinal cord cryosections from P18 
wild-type mice incubated with anti-α4 AB and DAPI. The figure demonstrates the higher density of α4 
containing neurons dorsally A, D, G:  Co-staining of α4-containing receptors (green) and nuclei of 
spinal cord cells (blue) by DAPI in the dorsal horn. B, E, H: Identical staining procedure on central area 
of the wild-type spinal cord. The arrow on picture E depicts nuclei of epithelial cells surrounding the 
central canal of the spinal cord. C, F, I: anti-α4/ DAPI co-staining of the ventral horn. The two arrows 
mark two motorneurons, which can easily be distinguished from other types of spinal cord neurons. 
Note differences of the density of α4 positive neurons between pictures A, B and C, whereas 
frequency of DAPI stained nuclei stays constant unimpaired of whether being localized dorsally (D), 
centrally (E) or ventrally (F) 
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Figure 17: α4 – containing nAChR are found in ventral horn motorneurons and dorsal horn 
interneurons. Photos depict immunofluorescence of 4% PFA post-fixed 16 µm thick thoracic spinal 
cord cryosections from P18 wild-type mice incubated with anti-α4 AB (green), synaptophysin 
(SYN,red) and DAPI (blue). A, B, C, D: Co-staining of a motorneuron in the ventral horn in high 
magnification. α4 signal could only be detected inside the cell perinuclearly. SYN outlines the cell, but 
there is no sign of α4-containing nAChR co-localizing with SYN on the surface of motorneurons. E, F, 
G, H: Co-staining of dorsal horn interneurons. Few co-localisation of SYN and α4 – containing nAChR 
could be observed, yielding yellow fluorescence. White arrows indicate a α4-positive and α4-negative 
neuron.    
 
β4 KO (We tried to pick representative pictures to denote differences between 
genotypes). Staining with our anti-α3 antibody showed signal pattern similar to α4 with less 
intensity.   Weak, but still specific signal could be identified in dorsal horn interneurons in 
the wild-type, whereas we detected no α3 positivity in motorneurons of ventral areas. In 
agreement with low levels of α3 subunit, as observed with IP measurements in β4 KO and β2 
KO mice, staining showed no specific signal in those two genotypes. Unfortunately, IHC with 
our anti β2 antibody gave only very sparse signal in wild-type and β4 KO spinal cord slices.  
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Figure 18: AB’s against different nAChR subunits show similar signal pattern. Photos depict 
immunofluorescence of 4% PFA post-fixed 16 µm thick thoracic spinal cord cryosections from P18 
wild-type, β4-KO and b2 KO mice incubated with anti-nAChR AB’s (green). Photomicrographs depict 
Immunofluorescence labeling of anti-α4 (A), anti-α3 (D), anti-β2 (G) in wild-type dorsal horn regions. 
Specificity of anti-α4 AB was better than anti-β2, since anti-α4 signal was much stronger, although 
these two subunits showed similar frequency in wild-type IP. Weaker signal of α3 compared to α4 in 
the wild-type goes in agreement with IP results. α4 signal was similar to wild-type in β4 KO mice (B) 
but diminished in β2KO (C). Anti-α3 yielded no specific fluorescence in β4 KO (E) and β2KO (F), 
whereas specific β2 signal could be detected in β4 KO (H), but not in β2 KO (I). 
 
Additionally the control of the anti-β2 AB in β2 KO animals demonstrates that there seems 
to be very slight unspecific background staining of neurons, which has to be subtracted from 
the already weak signal in wild-type and β4 KO.      
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4. Discussion 
 
Scarce data about the occurrence of a few subtypes in the spinal cord has been 
provided with the help of different selective agonists and antagonists (Khan et al., 2001; 
Young et al., 2008) but we are the first to give a detailed overview of the exact distribution 
and frequency of subunits and their association to form distinct subtypes. Our studies 
demonstrate, that nAChR’s show a great heterogeneity of subtypes in the mouse spinal cord, 
including combinations which contain only two subunits, as well as compositions containing 
three or four subunits. Fig. 19 is listing the proposed nAChR subtypes and their frequency in 
wild-type, β4 KO and β2 KO, which can be deduced from the experiments of this study. 
Consequently one of the main goals in the field of hetero-pentameric nAChR’s is to connect 
specific compositions to specific functions. With this study we tried to provide data for 
further investigations, which thus may be able to link a specific subtype of the spinal cord to 
a certain task.  
4.1 The choice of the β-subunit determines nAChR - pharmacology 
Previous investigations demonstrated that the pharmacological profile of 
heteromeric nAChR is reflected primarily by the presence of either the β2 or β4 subunit 
(Turner and Kellar, 2005). Within the range of hetero-pentameric nAChR most studies 
differentiate α4β2* and α3β4* containing receptors by their functional potency to different 
nicotinic agonists, as β2 has a certain liking to co integrate with α4, whereas β4 prefers α3. 
In contrast to the β-subunits, good assessment for the influence of different α subunits on 
pharmacological properties of nAChR is not possible at the moment. In general β2 containing 
nAChR’s show higher affinity for nicotinic agonists compared to nAChR’s which integrate β4. 
The Kd  for acetylcholine for example is four times higher in the α3β4* subtype (Jensen et al., 
2003; Xiao and Kellar, 2004) compared to α4β2*, meaning that in case you have both 
receptor subtypes in a synapse, only the α4β2-containing population is activated at a low 
concentration of neurotransmitter which reflects a possible regulatory mechanism for 
hetero-pentameric nAChR. Our results from the membrane binding experiments could 
confirm this difference of affinity between nAChR subtypes for the nicotinic agonist 
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epibatidine. The main difference of our experimental setup to a majority of similar 
investigations was the usage of native tissue. This was possible due the finding that the 
spinal cord of the wild-type consists of ~80% α4β2*, whereas mice lacking β2 showed 100% 
of the α3β4* subtype. Although 10% of α3β4* receptors can be found in the wild-type as 
well, their contribution is very likely negligible due to the much greater number of α4β2 – 
containing receptors. In comparison to our setup, most of the pharmacological data from 
nAChR subtypes has been observed in different cell lines and oocytes which were 
transfected with combinations of subunit mRNAs. Caveat of this technique is that there is 
probably a difference of nAChR’s expressed in vivo in comparison to nAChR’s expressed 
heterologously in oocytes and various cell lines due to potential different post-translational 
modifications and a different subcellular environment of the nAChRs. There are quite a lot of 
these modifications on nAChR as described in a review of Albuquerque (Albuquerque et al., 
2009). However, deduced from our experiments, the binding affinity for wild-type spinal 
cord, representing α4β2* was three times higher (~50 pM) than in β2 KO mice, representing 
α3β4*(~150 pM) and therefore did not much differ from findings in heterologous systems. In 
a previous study from our working group, consequently a Kd of 150 pM in the superior 
cervical ganglion (SCG) of wild-type mice, which contain a 100% α3β4* nAChR could be 
observed (David et al., 2010), supporting the veracity of our recent findings in the spinal 
cord.  
4.2 α4β2* predominates the spinal cord 
As demonstrated in results from our IP experiments, the dominance of α4β2 and 
α4β2* throughout various CNS regions (Flores et al., 1992; Whiting and Lindstrom, 1987; 
Perry et al., 2002) is consequently pertained in the spinal cord. Moreover we could show 
that 75 % of all nAChR of the wild-type spinal cord comprise only of these two subunits (Fig. 
19A). The rest of α4β2 containing receptors combined in traces with either an additional α2 
(α4β2α2 2%), α3 (α4β2α3 ~5%), α5 (α4β2α5 2%) or even possibly with α3β4 forming 
α4β2α3β4.  In cases where α4β2 combinations contain just one more additional subunit (e.g. 
α2, α3, α5) one might speculate that the difference is possibly rather small as the two 
binding sites of e.g. the two combinations α4β2α3 and α4β2α5 might be the same (always 
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between α4 and β2). A hypothetical α4β2α3β4 nAChR in contrast would definitely provide 
two different binding sites per receptor molecule between different α β interfaces. 
 Although the predominant role of α4β2 suggests a particular liking of these two 
subunits to assemble together in one receptor, we also found them in separation by 
detecting ~5% of receptors containing α4 but no β2 and another ~5% vice versa. This finding 
enhances the possible variation in which hetero-pentameric nAChRs can be composed of. 
The most prominent subtype where we could find β2 in isolation of α4 in the wild-type 
spinal cord is α3β2 (~5%), which has been described previously (Gotti et al., 2005) in the CNS 
and which we could additionally observe in β4KO animals. However, we showed association 
of α3 and β4 with α4 and β2 in our sequential IP experiments and therefore conclude 
(although at low frequency) that α3β4 containing receptors can be associated with either α4 
or β2 to form α3β4β2 and α3β4α4. We could observe the latter subtype in β2KO mice, 
corroborating that this composition can be formed in native tissue of mice.  
4.3 α3β4*is rare in the CNS and rare in the spinal cord 
α3β4 - containing receptors, although the dominant composition of the PNS in 
autonomic ganglia and the adrenal medulla, play a minor frequent role in the CNS. In the 
case of rodents, pure α3β4 and α3β4* (including various additional subunits) nAChR’s have 
been discovered in rat cerebellum (Turner and Kellar, 2005), rat pineal gland (Hernandez et 
al., 2004), rat retina (Marritt et al., 2005) and the mouse habenulo-interpeduncular pathway 
(Grady et al., 2009). Tissue of the latter structure (medial habenula and interpeduncular 
nucleus) is providing the main contribution of α3β4* receptors in the CNS of rodents 
(Scholze et al., submitted; (Marks et al., 2010). In this study we added the mouse spinal cord 
to the list of α3β4* containing CNS-areas as we could detect 10% α3β4* nAChR’s of which 
5% contain solemnly α3 and β4 subunits (α3β4), whereas the remaining 5% contain either an 
additional α4 (α3β4α4), β2 (α3β4β2) or both (α3β4α4β2). The strong preference of β4 to 
assemble with α3 together in one receptor is shown in this study with sequential IP, where 
precipitating α3 – containing receptors with our specific anti-α3 AB left no β4 – containing 
receptors behind.  
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Figure 19: Knock-out of β-subunits drastically reduces the variety of subtypes. A, B and C 
summarize the hetero-pentameric nAChR subtype variety deduced from results of IP and sequential 
IP in the spinal cord of wild-type, β4KO and β2KO. The asterisks next to the receptor compositions of 
the β4 KO in B indicate an additional possible α5 subunit in each occurring subtype of this genotype. 
In the case of wild-type (A) due to the contribution of many different subunits, some receptor 
subtypes could not be resolved completely. If more than one subtype is listed next to a percental 
share it means that this share can possibly contain all of the listed compositions, but doesn’t 
necessarily have to. D offers a comparison between the different genotypes regarding overall 
frequency of heteromeric nAChRs as determined by IP, which is not shown in the pie-charts.  
Statistical differences between columns were indicated by student’s t-test. ***, p<0.0005 
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4.4 How does the subunit composition change in response to complete 
lack of a β subunit? 
In order to take full advantage from the accessibility of β2- and β4- KO mice we 
analyzed consequent rearrangement of nAChR compositions as well as absolute numbers of 
nAChR’s to supplement results from experiments with wild-type spinal cords. The 
distribution of receptor subtypes in the spinal cord of the two knock-out animals is shown in 
figure 19. 
4.4.1 Loss of β-subunits is not compensated at all 
  Although β2 (in combination with α4) is accounting for the major part of nAChR 
subunits in the spinal cord and nearly all regions of the brain, we could not detect any means 
of compensation among the remaining nAChR subunits. Regarding receptor composition, the 
level of expressed β4 subunit in the β2-KO is as frequent as in the wild-type, so the 
transcription and expression of β4 is not influenced by the loss of β2 at all. A possible 
explanation of how β2KO neurons keep up a seemingly functioning cholinergic system in 
spinal cord with only 10% of the original number of hetero-pentameric nAChRs might be the 
fact that in wild-type, 65-85% of receptors are kept in intracellular pools (Fenster et al., 
1999; Pakkanen et al., 2006; Whiteaker et al., 1998). This circumstance might enhance the 
ability of hetero-pentameric nAChRs for turn-over and up-regulation under certain 
conditions. Possibly, the 10% of β4 receptors are enough to provide functional cholinergic 
synapses in the spinal cord of β2-KO mice under most conditions. 
However, interestingly the non-compensation for β2-KO has been also observed in 
regions within the CNS where β2 is the only β-subunit of hetero-pentameric nAChRs 
(Hippocampus, mouse P18, Scholze et al. unpublished). In case of β2 KO, hetero-pentameric 
nAChRs seem to be lost entirely in this region and not compensated by β4. Compensation for 
hetero-pentameric nAChRs by α7 homo-pentameric nAChRs is not likely as binding of α-
Bungarotoxin (α7 selective antagonist) in brain of wild-type and β2 KO mice is unchanged 
(Marks et al., 2010) 
In contrast to the dramatic uncompensated loss of β2 containing receptors in the 
spinal cord we could not observe any obvious phenotype (without animal testing) of β2 KO 
mice, demonstrating that the consequences of β2 deficiency are more subtle as shown in 
different publications (Picciotto et al., 1995; Picciotto et al., 1998; Marubio et al., 1999)  To 
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understand how the CNS is coping with the loss of certain receptor subtypes or the complete 
loss of all hetero-pentameric nAChRs in certain tissues and the consequences of these 
changes will be a challenging task for future investigations. 
4.5 Preferences of subunits in choosing partners  
Although there seems to be no compensation for knocked out subunits, we did 
observe decrease of integration of certain subunits into hetero-pentameric nAChRs in β2- 
and β4-KO animals. However, at this point, it should be considered that our IP shows the 
amount of [³H]-epi binding to dimers, trimers and heteromers which contain a specific 
subunit. If a certain subunit is less integrated into such a complex in β2- or β4-KO animals it 
can be due to two reasons. A: Due to the KO of a β subunit, there might be down-regulation 
in transcription or translation of other subunits. B:  The expression or translation of a certain 
subunit is the same in wild-type and KO, but the subunit less likely integrates together with 
subunits that are left after β-subunit KO.  
4.5.1 α3 and β4 like each other  
One example for this phenomenon was the drop of the α3 subunit from 18% in the 
wild-type to 4% in the β4KO. As discussed above, β4 has a liking to co-integrate into a 
receptor together with α3 as all β4 containing receptors in the wild-type possess α3. From 
the ~20% (compared to all nAChR) of α3-containing receptors in the wild-type, ~10% go 
together with β4 to form α3β4*, whereas ~10% form either the subtype α3β2 or α3α4β2. In 
the β4KO spinal cord there are not only all α3β4-receptors lost, also the α3β2 and α3α4β2 
containing receptors (which make up for 10% of heteromeric nAChRs in the wild-type) are 
decreased to 4%. (As the 100% value in WT and β4 KO is similar at around 43 fmol/mg MP it 
is accurate to compare percentages between these two genotypes which refer to  the 100% 
value of the respective genotype). As the composition α3β2 and α3α4β2 as mentioned 
above is possible, not finding a functional partner to form hetero-pentameric nAChR’s in the 
β4KO neurons cannot be the reason for the α3 subunit levels to drop this dramatically. 
Therefore our experiments in the β4 KO demonstrate that the expression of α3 in hetero-
pentameric nAChRs is negatively influenced by the lack of β4.  This is not completely 
surprising given the fact that α3 (CHRNA 3), α5 (CHRNA5) and β4 (CHRNB4) are genetically 
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associated in a cluster on chromosome 15 (Berrettini, 2008) whereby the KO of β4 may 
influence gene transcription of the whole cluster.  
In the case of β2 KO animals, α3 is leveled to exactly match the frequency of β4, 
resulting in a decrease from 8 fmol/mg MP in the wild-type to 4 fmol/mg MP in the β2KO. As 
we measure whole receptors (and not subunits) with IP it is not necessarily the transcription 
and translation of α3-subunit, which is affected by the KO of β2. It is more likely that α3 
subunits are translated in similar amounts as in the wild-type whereas the amount of β4-
subunits (the only β-subunit partner for α3 in the β2KO) is the limiting factor. In the wild 
type, the amount of α3-containing receptors is two times the number of β4-containing 
receptors, in which case α3β2* receptors are formed besides α3β4. 
4.5.2 α4 has no particular interest in β4  
In contrast to the liking of α3 and β4 to form receptors, in the β2KO, the level of α4 
shows reduction below the level of β4 containing receptors to only ~1fmol/mg MP , which is 
conform to ~30% of all receptors which are expressed in the β2KO. We cannot determine if 
the expression of the α4 subunit is influenced by the KO of β2, but if we suggest similar 
levels of translated α4 subunits in this genotype as in the wild-type (where it is expressed in 
much higher frequency: 43 fmol/mg MP), the fact that α4 doesn’t even level the 4 fmol/mg 
MP in the β2 KO (it only shows 1 fmol/mg MP) shows that its ability to form the α3β4α4 – 
subtype with α3 and β4 is limited.  
In this study, the subtype mentioned above (α3β4α4) was the only one where α4 and 
β4 could be found together in one receptor. This is in contradiction to findings of the α4β4 
subtype in the IPN of β2KO mice (Klink et al., 2001) and cerebellum and retina of the rat 
(Turner and Kellar, 2005; Marritt et al., 2005).  
4.5.3 α2 and α5 rather integrate with α4β2 than α3β4  
 The minor frequent subunits α2 and α5 (~2fmol/mg MP in wild-type each) are not 
affected by the KO of β4, leading to the suggestion that these two subunits co-integrate 
preferentially together with β2. As α5 is accessory this would result in the subtype α5α4β2, 
but not α5β2. Concerning α2, the α2α4β2 subtype is possible, but also the assembly of α2β2 
receptors has been reported in the rat retina (Moretti et al., 2004) and the rat IPN (Gotti et 
al., 2005). The fact, that β2 showed significantly higher levels than α4 in IP of β4KO mice 
might be an indication that α2β2 is preferred over α2α4β2 as there is not enough α3 and α4 
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to cope with the β2 – levels in this genotype. The levels of α2 and α5 in β2KO animals are 
below 0.3 fmol/mg MP, a protein concentration which is very likely beyond the level of our 
detection system. However, it is a fact that α2 and α5 levels drop dramatically in the β2KO 
(In terms of fmol/mg MP, the percentage of α2 and α5 is higher in β2KO because the 100% 
value is much lower), but stay the same in the β4KO. This strengthens the suspicion that α5 
and α2 form receptors with β2 in the wild-type spinal cord.  
Investigations of the α5 subunit revealed different results. As α5 has been shown to 
co-integrate preferentially with β4 to form α3β4α5 in autonomic and sensory ganglia (David 
et al., 2010; Mao et al., 2006; Conroy and Berg, 1995), it only forms receptors with α4 and β2 
(α4β2α5) in various CNS regions of the brain (Mao et al., 2008; Gerzanich et al., 1998; Gotti 
et al., 2005; Lomazzo et al., 2010; Zoli et al., 2002). Therefore the decision of α5 to form 
receptors with either β2 or β4 is probably made by the dominance of either α3β4 or α4β2 in 
the according region.  
A hypothetical α2α5β2 receptor would also be possible in the spinal cord but this 
subtype has not been shown yet in mammals and due to the low levels of α2 and α5, the 
claim of its existence would be highly speculative.   
4.6 Can localization of nAChRs in the spinal cord be aligned to the 
analgetic effect of intrathecally injected nicotinic agonists?  
Although the pharmacological and biophysical profile of the various subtypes of 
hetero-pentameric nAChR’s is, thanks to numerous studies, a detailed one, exact 
morphological data is rather rare. The major reasons for this circumstance is on one hand 
the problematic of producing specific AB against the different existing subunits (Moser et al., 
2007) and on the other hand the lack of adequate KO-controls (see introduction).  
Our findings in immunohistochemistry (IHC) and autoradiography confirmed the 
findings that nAChR’s in the spinal cord of wild-type mice tend to show much heavier 
labeling in dorsal layers than ventral areas of the grey matter (Khan et al., 2003). In more 
detail, the observed signal of our antibodies against the specific subunits α3, α4 and β2 
showed strong labeling of cell soma from interneurons or projection neurons in the dorsal 
horn and much lighter labeling of motorneurons in the ventral horn. This dorsal polarity is in 
agreement with the assumption that spinal nAChR’s play a role in the transfer of nociceptive 
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stimuli over C-Fibres, which are relaying to soma of projection neurons and interneurons at 
dorsal layers of the spinal cord.  
At least two reasons might contribute to our observed strong intracellular signal. 
Firstly, as mentioned above, cytoplasmatic pools account for the majority of total 
pentameric receptors in a nAChR-expressing cell. Secondly AB’s bind specific subunits not 
receptors and therefore consequently label single subunits, dimers and trimers as well as 
functional pentamers. These factors impede the task of pinpointing active nAChR at synaptic 
varicosities on neuronal cell bodies as it is hard to tell where the Cytoplasm ends and a 
potential synapse starts although we could observe some co-localization of nAChR from 
interneurons and/or projection neurons in the dorsal horn with synaptophysin. As 
synaptophysin is a presynaptic marker, this would impede that hetero-pentameric nAChR sit 
pre-synaptically on axons of DRG neurons which reach into dorsal areas of the grey matter 
to connect to projection and/or interneurons. However due to the strong intracellular 
staining in these interneurons and/or projection neurons we cannot exclude postsynaptic 
occurrence of hetero-pentameric nAChR either.  
Clearly no synaptic signal of immunoreactivity with our anti-nAChR ABs could be 
observed in motorneurons in ventral areas, although we could detect some sort of a peri-
nuclear staining, especially with the anti-α4 AB. As nAChR are folded and oligomerized in the 
endoplasmatic reticulum (Green and Claudio, 1993; Gaimarri et al., 2007; Ren et al., 2005) 
before they are transported to synaptic varicosities at the cell membrane our observations in 
motorneurons suggest the assumption that nAChR subunits are translated, but not 
expressed as functional pentamers which leave the ER. The observed strong vAChT 
immunoreactivity around the motorneurons arises from C-Boutons, which are known to 
contain muscarinic AChRs (Miles et al., 2007) but according to our stainings no 
heteropentameric nAChRs. These results lead us to believe that heteropentameric nAChRs 
are transcribed and translated in neurons in dorsal and ventral areas, wherefore it is possible 
to obtain positive signal in IHC and autoradiography in dorsal and ventral areas, but their 
participation in synaptic transmission seems to be restricted to dorsal areas of the grey 
matter. 
Regarding immunoreactivity of different subunits, we could not detect any 
differences concerning the location of staining from AB against α3, α4 and β2 and therefore 
it is not likely that different subunits are restricted to different specific areas in the spinal 
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cord. Still, as we were not able to obtain signal from β4 and the minor frequent subunits of 
the spinal cord, α5 and α2, this possibility remains.     
4.7 Contribution of nAChR – subtypes to transmission and modulation 
of pain-mediated pathways 
An important point about investigating the pain alleviation by nicotinic agonists in 
rodents would be to assign the effect to certain nAChR – subtypes. According this especially 
the KO of specific subunits and the intrathecal injection of selective nicotinic agonists have 
been the methods of choice. Analysis of KO animals have demonstrated that analgesia due 
to injection of nicotine is less effective in α4KO and β2KO animals tested in pain tests specific 
for spinal mechanisms (Marubio et al., 1999). This notion is supported by numerous reports 
about pain relieving effects of potent agonists which are specific for the α4β2* receptor 
(Khan et al., 1998), which is in accordance to our findings that the α4β2* subtype occurs in 
high frequency in the spinal cord and are therefore likely involved in pain-mediated 
pathways. However, on the other hand, it has been demonstrated recently that some 
agonists (e.g. varenicline and ABT-594), which were believed to activate α4β2 only, also 
activate α3β4 receptors (Gao et al., 2010). Furthermore this study showed that the anti-
nociceptive effects of thoroughly tested α4β2 - selective agonists never showed the same 
strength like full agonists indicating that the α4β2* subtype is necessary, but maybe not 
sufficient to elicit analgesia by itself. Consequently, it is possible that our proposed 10% of 
the α3β4* subtype also plays an important role in spinal pain transmission. Interestingly, 
although we only detected marginal amounts of α5-containing receptors in the spinal cord, it 
has been shown that nicotine induced analgesia is greatly diminished in α5-KO mice(Jackson 
et al., 2010). Combined with our results the conclusion might be that α4β2α5 receptors in 
the grey matter are located restrictive to areas of pain transmission. Also α7 homo-
pentameric receptors have been reported to be involved in spinal pain processing as α7 
specific antagonists can neutralize the anti-nociceptive effect of nicotine (Damaj et al., 
1998b; Damaj et al., 2000; Khan et al., 2001).  
As a consequence to the apparent involvement of different nAChR subtypes it is very 
likely that there is more than one mechanism involved in modulating and transmitting pain 
signals at the spinal cord level. In order to get clinical benefit from the analgetic potential of 
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nicotinic agonists on spinal cord level, more information about the exact site of action and 
the mechanism itself is needed.  
4.8 Occurrence of receptors identifies the site of nAChR action, mRNA 
levels the site of nAChR synthesis 
From the subtypes, which might be involved in mediating pain relief at spinal cord 
level, we could detect α3β4* and α4β2* (among them α4β2α5) with IP. Surprisingly, 
although finding decent levels of α3 and β4 – containing receptors in the wild-type spinal 
cord with the help of IP (20% and 10% respectively), mRNA levels of α3 and especially β4 
were barely detectable in RT-PCR analysis of wild-type spinal cord tissue. When screening 
literature we found several different studies backing up the notion that there are no mRNA 
levels of β4 transcripts in rodent spinal cord tissue (Zoli et al., 1995; Dineley-Miller and 
Patrick, 1992). A plausible explanation for the expression of subunits in heteromeric nAChRs 
in the spinal cord with no mRNAs could be that instead of being transcribed in neurons 
whose soma sit in the spinal cord, these two subunits are rather produced by dorsal root 
ganglion (DRG) neurons, whose axons express α3β4* receptors inside the spinal cord (which 
would explain results from IP) presynaptically (Fig. 20). Further evidence for this scenario are 
provided by Boyd and Genzen (Boyd et al., 1991; Genzen et al., 2001), which showed strong 
levels of α3 and β4 mRNA levels in DRGs of rodents. A very similar situation has been 
described in the habenulo-Interpeduncular pathway, where α3β4* receptors in the 
interpeduncular nucleus sit on presynaptic axonal terminals, which origin in the medial 
habenula (Gotti et al., 2009). Therefore α3β4* receptors could be detected in the IPN by IP, 
but no α3 or β4 mRNA levels by RT-PCR.     
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Figure 20: α3β4 – containing receptors might origin in the soma of dorsal root ganglia      The lower 
panel displays a transverse section of the spinal cord including dorsal root ganglia (DRG).  DRGs 
contain soma of afferent sensory neurons, including pain mediating Aβ- and Aδ- fibres (red). Axons of 
these fibres enter the dorsal horn of the spinal cord grey matter and connect to soma of 
interneurons- and/or projection neurons (blue). The left upper panel shows a simplified scheme of 
axonal afferences connecting to soma of projection-or interneurons in the grey matter. As mRNA 
levels of α3 and β4 are very low to non-existent in the grey matter (whereas α3β4 receptors can be 
found) it is possible that this subtype is transcribed by DRG neurons and expressed presynaptic on 
their axonal terminals in the grey matter. Of the various subtypes which can be transcribed and 
expressed by neurons, whose soma sit in the grey matter, only the most abundant hetero-
pentameric nAChR α4β2 is depicted in this simplified overview.  
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Although our data from IHC provide some insight into possible localization of 
different nAChR- subunits many questions about the cholinergic role in pain transmission 
over the spinal cord remain unanswered. One major problem is the complexity of the spinal 
network, which is affecting the transmission of nociceptive stimuli on the spinal cord level. 
Recent investigations on the physiological role of afferent cholinergic innervation have 
shown that nicotinic agonists evoke inhibitory post-synaptic potentials (IPSPs) via GABA 
evoked currents (Matsumoto et al., 2007; Gao et al., 2010), which would mean that hetero-
pentameric nAChRs sit presynaptic and release GABA via binding of acetylcholine. However, 
there are still plenty of possibilities of how these interneurons can be relayed to either the 
afferent neuron or the projection neuron, which transmits the signal to supra-spinal levels of 
pain procession or in reflex arcs to motor neurons.   
There seems to be consensus that presynaptic hetero-pentameric nAChRs tend to 
play a bigger role than postsynaptic receptors  (Albuquerque et al., 2009). Therefore, for 
understanding mechanisms of cholinergic signaling, a crucial task will be investigating which 
types of neurotransmitters (next to GABA) can be released by activation of different 
heteromeric nAChRs. 
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